Prostate-specific membrane antigen targeted compounds and use thereof
Radiopharmaceuticals targeting PSMA are developed for safe and effective imaging and treatment of cancer by utilizing a chelator-radionuclide complex with a targeting molecule and linker, addressing the need for targeted cancer therapies.
Patent Information
- Application Number
- PCT/US2026/026591
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for radiopharmaceuticals that can be safely and effectively used for the imaging and/or treating of cancer and other disease states, particularly those targeting prostate-specific membrane antigen (PSMA) to address the challenges in diagnosing and treating diseases with high expression in cancer microenvironments.
Development of radiopharmaceuticals designed as Y-L-X, where Y is a chelator that stably complexes a radionuclide, X is a targeting molecular structure that binds to PSMA, and L is a molecular linker, allowing for targeted delivery to cancer cells.
The developed radiopharmaceuticals provide effective imaging and therapeutic options for cancer treatment by leveraging PSMA expression, enhancing diagnostic accuracy and treatment efficacy.
Smart Images

Figure US2026026591_12112026_PF_FP_ABST
Abstract
Description
[0001] PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED COMPOUNDS AND USE THEREOF
[0002] CROSS REFERENCE TO RELATED APPLICATIONS
[0003] The present application claims benefit of U. S. Provisional Patent Application Serial No.
[0004] 63 / 800,228, filed on May 5, 2025, the entire content of which is hereby incorporated by reference.
[0005] BACKGROUND
[0006] Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein that is overexpressed in certain cancer cells, such as prostate cancer epithelial cells. PSMA expression can increase with several factors including higher tumor stage and grade, tumor differentiation, hormone resistance, and metastatic disease. Although PSMA first was identified in the prostate gland, its expression in the other cancerous tissues such as duodenal epithelium, proximal tubule cells in the kidney, salivary glands, and tumor-associated vascular endothelium, has been found in histopathological studies. PSMA contains a binuclear zinc site and is active as a glutamate carboxy peptidase. (Davis et al, Crystal Structure of Prostate-Specific Membrane Antigen, a Tumor Marker and Peptidase, Proc. Natl. Acad. Sci. 102(17) 5981-5986 (Apr 18, 2005)). PSMA can be characterized by the murine monoclonal antibody (mAb) 7E11-C5.3 and is expressed in all forms of prostate tissue, including carcinomas. Certain studies have found the PSMA protein to have a unique 3-part structure, including a 19-amino-acid internal portion, a 24-amino-acid transmembrane portion, and a 707-amino-acid external portion. The PSMA gene is located on the short arm of chromosome 11 in a region that is not commonly deleted in prostate cancer. (Chang, Overview of Prostate-Specific Membrane Antigen, Rev. Urol. 6 (Suppl I0): S13-S18 (2004)). Previous studies have also shown that PSMA undergoes internalization, which makes PSMA an attractive target for imaging and therapeutic applications. (Rogers et al.. Targeted Delivery of Cytotoxic Proteins to Prostate Cancer via Conjugation to Small Molecule Urea-based PSMA Inhibitors, Scientific Reports 11, 14925 (2021)).
[0007] The high expression of PSMA in the cancer microenvironment compared with adjacent normal tissue makes PSMA a potential therapeutic target for drag delivery. Within this context, radiopharmaceuticals targeting PSMA are of particular potential. Radiopharmaceuticals are radiolabeled drags that are used for imaging and / or therapy of disease. These drugs may bedesigned with the form Y-L-X, where Y is a chelator that stably complexes (i.e., binds tightly) a radionuclide (e.g., Pb-212, Ac-225, Lu- 177, Cu-64, Cu-67, Ga-68, Pb-203) that decays by various forms of radioactive decay modes (e.g., beta-particle emission, alpha-particle emission, positron emission, gamma-ray emission, auger electron emission); X is a targeting molecular structure (e.g., peptide, antibody, small molecule, aptamer) that is designed to bind to cells, often by binding to a cell surface receptor (e.g., g-protein coupled receptor, type II glycoprotein, or other antigen, potentially expressed inside the cell); and L is a molecular linker that connects the chelator Y to the binding moiety X.
[0008] The use of certain radionuclides that emit gamma rays enables imaging that can be used for diagnosing and monitoring of disease. Other radionuclides that emit particles, such as beta and alpha particles, are used for treating diseases, such as cancers. In some cases, the radionuclides intended for the treatment of cancer or other diseases, decay further to a series of radionuclide progeny (often referred to as daughter radionuclides or “daughters”) that may or may not be complexed by the chelator. The preparation of radiopharmaceuticals involves a reaction of the Y -L-X precursor with the radionuclide. Examples of radionuclides used for this purpose that have a series of daughter radionuclide progeny in their series includes Pb-212, Ga-68 and Lu- 177.
[0009] Accordingly, there remains a need for radiopharmaceuticals that can be safely and effectively used for the imaging and / or treating of cancer and other disease states.
[0010] DETAILED DESCRIPTION OF THE DRAWINGS
[0011] To facilitate further description of the embodiments of this disclosure, the following drawings are provided to illustrate and not to limit the scope of the disclosure.
[0012] FIG. 1A-1D show radiochemical purity as measured by HPLC for reference compound 203-Pb-PSMA-617, and 203-Pb-PSMA-3B at end of synthesis (EOS) and after 24 hours in saline.
[0013] FIGS. 2A-2B show the IC50 of reference compound PSMA-617, and PSMA-3B.
[0014] FIG. 3A shows uptake on LNCaP at 37°C of reference compound 203-Pb-PSMA-617, and 203-Pb-PSMA-3B.
[0015] FIG. 3B shows efflux from LNCaP cells for reference compound 203-Pb-PSMA-617, and 203-Pb-PSMA-3B.FIG. 4 shows biodistribution of 203-Pb-PSMA-3B in nude mice bearing a LNCaP xenograft.
[0016] FIG. 5 A shows gamma-eye imaging of reference compound 203-Pb-PSMA-617, and 203-Pb-PSMA-3B.
[0017] FIG. 5B shows ex-vivo biodistribution at 21 hours post- injection of reference compound 203-Pb-PSMA-617, and 203-Pb-PSMA-3B.
[0018] DETAILED DESCRIPTION OF THE INVENTION
[0019] Definitions
[0020] As used herein, the terms “comprising”, “having”, “including”, and “containing” and grammatical variations thereof, are inclusive or open-ended and do not exclude additional, unrecited elements and / or method steps, even if a feature / component defined as a part thereof consists or consists essentially of specified fcaturc(s) / componcnt(s). The term “consisting essentially of’ if used herein in connection with a compound, composition, use or method, denotes those additional elements and / or method steps may be present, but that these additions do not materially affect the manner in which the recited compound, composition, method or use functions. The term “consisting of’ if used herein in connection with a feature of a compound, composition, use or method, excludes the presence of additional elements and / or method steps in that feature. A compound, composition, use or method described herein as comprising certain elements and / or steps may also, in certain embodiments consist essentially of those elements and / or steps, and in other embodiments consist of those elements and / or steps, whether or not these embodiments are specifically referred to. A use or method described herein as comprising certain elements and / or steps may also, in certain embodiments consist essentially of those elements and / or steps, and in other embodiments consist of those elements and / or steps, whether or not these embodiments are specifically referred to.
[0021] A reference to an element by the indefinite article “a” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. The use of the word “a” or “an” when used herein in conjunction with the term “comprising” may mean “one”, but it is also consistent with the meaning of “one or more”, “at least one” and “one or more than one”.In this disclosure, the recitation of numerical ranges by endpoints includes all numbers subsumed within that range including all whole numbers, all integers and, where suitable, all fractional intermediates (e.g., 1 to 5 may include 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5 etc.).
[0022] Unless otherwise specified, “certain embodiments”, “various embodiments”, “an embodiment” and similar terns includes the particular feature(s) described for that embodiment either alone or in combination with any other embodiment or embodiments described herein, whether or not the other embodiments are directly or indirectly referenced and regardless of whether the feature or embodiment is described in the context of a method, product, use, composition, compound, et cetera.
[0023] With regard to stereoisomers, it should be understood that a solid line designation for the bonds in the compositions corresponding to the structural formulae disclosed herein for attachment of a substituent group to a chiral carbon atom of the compound may indicate that these groups may lie either in, below or above the plane of the page (i.e., all isomeric forms of the compounds disclosed herein are contemplated, including racemates, racemic mixtures, and individual enantiomers or diastereomers). Certain compounds described herein may exist in tautomeric forms, and all such tautomeric forms of the compounds being within the scope of the disclosure.
[0024] The term "acyl," as used herein alone or as part of another group, denotes the moiety fomied by removal of the hydroxyl group from the carboxy group, -COOH, of an organic carboxylic acid, e.g., X C(O)-, wherein X4 is X1, XLO-, X^N-, or X^-, X1is hydrogen, optionally substituted hydrocarbyl, or heterocyclo, and X2is hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo. In certain embodiments, X1and X2are independently optionally substituted alkyl, optionally substituted alkenyl, aryl, or heterocyclo. Exemplary acyl moieties include acetyl, propionyl, benzoyl, pyridinyl, carbonyl, and the like.
[0025] The term "aliphatic" denotes saturated and non-aromatic unsaturated hydrocarbyl moieties having, for example, one to about twenty carbon atoms or, in specific embodiments, one to about twelve carbon atoms, one to about ten carbon atoms, one to about eight carbon atoms, or even one to about four carbon atoms. The aliphatic groups include, for example, alkyl moieties such as methyl, ethyl, n-propyl, isopropyl, n butyl, isobutyl, sec -butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like, and alkenyl moieties of comparable chain length. As used herein, the term “alkyl group” encompasses saturated linear or branched carbon radicals having, for example, one to about twenty carbon atoms or, in specific embodiments, one to about twelve carbon atoms. In other embodiments, alkyl groups arc "lower alkyl" groups having one to about eight carbon atoms.Examples of such groups include, but are not limited thereto, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -butyl, tert-butyl, pentyl, iso-amyl, hexyl, ethylhexyl, octyl and the like.
[0026] The term "alkyl" as used herein, alone or as part of another group, denotes saturated linear, branched or cyclic carbon radicals having, for example, one to about twenty carbon atoms or, in specific embodiments, one to about twelve carbon atoms. In certain embodiments, alkyl groups are "lower alkyl" groups having one to about six carbon atoms. Examples of such groups include, but are not limited thereto, methyl, ethyl, n-propyl, isopropyl, n butyl, isobutyl, sec-butyl, tertbutyl, pentyl, iso-amyl, hexyl and the like. In more specific embodiments, lower alkyl groups have one to four carbon atoms.
[0027] The term “alkylene” as used herein, alone or as part of another group, denotes a linear saturated divalent hydrocarbon radical of one to twenty carbon atoms, or, in specific embodiments, one to about six carbon atoms or a branched saturated divalent hydrocarbon radical of three to twenty carbon atoms unless otherwise stated, e.g., methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.
[0028] The term "alkenyl" as used herein, alone or as part of another group, denotes linear, branched or cyclic carbon radicals having at least one carbon-carbon double bond. The term "alkenyl group" can encompass conjugated and non-conjugated carbon-carbon double bonds or combinations thereof. An alkenyl group, for example and without being limited thereto, can encompass two to about twenty carbon atoms or, in a particular embodiment, two to about twelve carbon atoms. In certain embodiments, alkenyl groups are "lower alkenyl" groups having two to about six carbon atoms. Examples of alkenyl groups include, but are not limited thereto, ethenyl, propenyl, allyl, vinyl, butenyl and 4-methylbutenyl. The terms "alkenyl group" and "lower alkenyl group", encompass groups having "cis" or "trans" orientations, or alternatively, " E" or " Z" orientations.
[0029] The term "alkoxy," as used herein alone or as part of another group, denotes an -OX5radical, wherein X5is as defined in connection with the term "alkyl." Exemplary alkoxy moieties include methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or tert-butoxy, cyclohexyloxy and the like.
[0030] The term "amide," as used herein, alone or as part of another group, denotes a group having the formula -C(O)N(X8)(X9), wherein Xsand X9are as defined in connection with the terms "amine" or "amino." For example, "substituted amide" refers to a group of
[0031] formula -C(O)N(X8)(X9), wherein at least one of X8and X9are other than hydrogen and“unsubstituted amido," for example, refers to a group of formula -C(O)N(X8)(X9) wherein each of X8and X9are hydrogen.
[0032] The terms "amine" and "amino" as used herein, alone or as part of another group, are used interchangeably and denote a group of formula *-N(X8)(X9), wherein * denotes the point of attachment of the moiety to the remainder of the molecule and X8and X9are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl, heteroaryl, or heterocyclo, or X8and X9taken together form a substituted or unsubstituted alicyclic, aryl, or heterocyclic moiety, each as defined in connection with such term, typically having from 3 to 8 atoms in the ring.
[0033] " Substituted amine," for example, refers to a group having the formula -N(X8)(X9), wherein at least one of X8and X9are other than hydrogen and “unsubstituted amine” refers to a group having the formula -N(X8)(X9), wherein each of X8and X9are hydrogen.
[0034] The term “amino acid,” includes naturally occurring amino acids (including L and D isostereomers) and residues thereof, and unless otherwise limited, and also include known analogs of natural amino acids or amino acids derivatives that can function in a similar manner as the common natural amino acids, such as selenocysteine, naphthylalanine, anthrylalanine, norleucine, pyrrolysine, N-formylmethionine, gamma-carboxyglutamate, hydroxyprolinehypusine, pyroglutamic acid, selenomethionine, 1 -naphthylalanine (1-Nal), 2-naphthylalanine (2-Nal), 3-(4-biphenyl-alanine (Bip), 2-pyridyl-alanine (2-Pal), 3-pyridyl-alanine (3-Pal), 4-pyridyl-alanine (4-Pal), 3-benzothienyl-alanine (Bta), 2-cyano-phenylalanine, 3-cyano-phcnylalaninc, 4-cyano-phcnylalaninc, 3-borono-phcnylalaninc, 4-borono-phenylalanine, 4-trifluoromethyl-phenylalanine, 2-chloro-phenylalanine, 3 -chloro-phenylalanine, 4-chloro-phenylalanine, 2-fluoro-phenylalanine, 3 -fluoro-phenylalanine, 4-fluoro-phenylalanine, 2-iodo-phenylalanine, 3 -iodo-phenylalanine, 4-iodo-phenylalanine, 2-methyl-phenylalanine, 3-methyl-phenylalanine, 4-methyl-phenylalanine, 2-nitro-phenylalanine, 3 -nitro-phenylalanine, 4-nitro-phenylalanine, 4-pentafluoro-phenylalanine, phenylglycine (Phg), 4-amino-phenylalanine, 4-methoxy-phenylalanine, 5-hydroxytrptophan, 3, 5 -diiodo-tyrosine, 4-benzoyl-phenylalanine, 5-hydroxy-trptophan, 3, 5-diiodo-tyrosine, 4-benzoyl-phenylalanine (Bpa), cyclohexylglycine (Chg), or 2-thienyl-alanine (Thi). (see, e.g., Ho J et aL, ACS Synth Biol 5: 163-71 (2016); Wang Y, Tsao M, Chembiochem 17: 2234-9 (2016)).
[0035] The terms “amino acid sequence” and “peptide sequence” are used interchangeably herein and denote a series of amino acid residues linked via amide bonds, and depending upon the number of residues in the series comprise a peptide, polypeptide or protein.As used herein, the term "aralkyl" denotes an alkyl radical, substituted by one or more aryl moieties, wherein the linkage to the remainder of a moiety is through the alkyl radical.
[0036] As used herein, the term "aralkylene" denotes a divalent chain of 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, more typically 1 to 10 carbon atoms, and most typically 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms that can be saturated or partially unsaturated, containing one or more aryl moieties. The aryl moiety may be a part of a pendant (or
[0037] side) group attached to a chain of atoms (e.g., wherein * denotes the point of attachment of the aralkylene moiety to the remainder of the molecule, or two or more atoms of the
[0038] aryl moiety may also serve as chain atoms of the aralkylene moiety (e.g.,
[0039]
[0040] The term "aromatic" as used herein, alone or as part of another group, includes “aryl” and “heteroaryl” groups as defined herein.
[0041] The terms "aryl" and “Ar” as used herein, alone or as part of another group, are used interchangeably and denote an aromatic group having one or more rings wherein such rings may be attached together in a pendent manner or may be fused. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, and anthryl. Unless specified otherwise, the aryl group may be substituted at one or more ring positions with hydroxyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, acyl, acyloxy, amino, aryloxy, carboxy, cyano, halogen, mercapto, oxo, nitro, thiol, sulfo, or the salts thereof.
[0042] As used herein, a “binding peptide” or a “conjugate having the binding peptide that binds a cellular target of interest” is one that binds the cellular target with sufficient affinity that is measurably different from a non-specific interaction. Selective binding can be measured, for example, by determining the binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity.
[0043] As used herein, a “branching moiety” refers to an atom or group of atoms having at least 3 positions that are capable of forming covalent linkages to at least 3 groups. In certain embodiments, a branching moiety may be a carbon atom. In other embodiments, it is a cyclic moiety having several sites for directly or indirectly connecting two binding peptides to a chelator capable of coordinating a radionuclide.As used herein, the terms “cancer” and “cancerous” refer to or describe the pathological condition in mammals that is typically characterized by unregulated or uncontrolled cell growth. A “tumor” comprises one or more tumor cells. Examples of cancer or tumor may include, but are not limited to, carcinoma, melanoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), skin cancer, melanoma, lung cancer including small-cell lung cancer (SCLC), non-small cell lung cancer (“NSCLC”), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), glioblastoma, cervical cancer, ovarian cancer (e.g., high grade serous ovarian carcinoma), liver cancer (e.g., hepatocellular carcinoma (HCC)), bladder cancer (e.g., urothelial bladder cancer), oral cancer, testicular (germ cell tumor) cancer, desmoid tumor, chordoma, pheochromocyto a, medullary thyroid cancer, gastric cancer, hepatoma, breast cancer, brain cancer (e.g., astrocytoma), colon cancer, rectal cancer, colorectal cancer, rectal adenocarcinoma, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer (e.g., renal cell carcinoma, nephroblastoma or Wilms’ tumor), prostate cancer, vulval cancer, thyroid cancer (including differentiated), insulinoma, hepatic carcinoma, anal carcinoma, small intestine cancer, penile carcinoma, as well as head and neck cancer. Additional examples of cancer include, without limitation, retinoblastoma, thecomas, arrhenoblastomas, hepatoma, hematologic malignancies including non-Hodgkins lymphoma (NEIL), multiple myeloma and acute hematologic malignancies, endometrial or uterine carcinoma, endometriosis, fibrosarcomas, choriocarcinoma, salivary gland carcinoma, vulval cancer, thyroid cancer, multiple myeloma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, follicular lymphoma, esophageal carcinomas, hepatic carcinoma, anal carcinoma, penile carcinoma, nasopharyngeal carcinoma, laryngeal carcinomas, Kaposi’s sarcoma, melanoma, skin carcinomas, Schwannoma, oligodendroglioma, neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma, osteosarcoma, leiomyosarcomas, urinary tract carcinomas, anaplastic astrocytoma, basal cell carcinoma (basal cell epithelioma), bile duct cancer, small cell bladder cancer, metastatic breast cancer, metastatic colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, gastric adenocarcinoma, glioblastoma multiforme (GBM), recurrent glioblastoma multiforme (GBM), gliomas, gliosarcoma, head and neck squamous cell carcinoma (HNSCC), recurrent head and neck squamous cell carcinoma, malignant pleural mesothelioma head and neck cancer, Hodgkin lymphoma, metastatic renal cell carcinoma, metastatic renal clear cell carcinoma, squamous non-small cell lung cancer, hepatocellular cholangiocarcinoma, thymoma type b2, ge junction adenocarcinoma, signet-ring cell carcinoma,gi stromal tumor, squamous carcinoma of the lung, relapsed or refractory small-cell lung cancer, treatment-resistant melanoma, metastatic melanoma, Merkel cell carcinoma, neuroendocrine cancer, large cell neuroendocrine cancer, neuroendocrine tumors (NETS), ovarian carcinoma, papillary carcinoma, peritoneal cancer, neuroendocrine prostate cancer, hormone- refractory prostate cancer, castration-resistant prostate cancer, soft tissue sarcoma, and squamous cell carcinoma.
[0044] The terms “carbocyclic,” “carbocycle” and “carbocyclyl” as used herein alone or as part of another group, are used interchangeably and denote any mono-, bi-, or tricyclic ring system in which the ring atoms are exclusively carbon and the ring system contains at least one aliphatic carbon-carbon bond. For example, the carbocycle may be cyclohexane, cycloheptane, and norbomane. Unless specified otherwise, the carbocyclic group may be substituted at one or more ring positions as described for heterocycles. The terms "carbocycle" and "aryl" are mutually exclusive.
[0045] The term "carboxy" and “carboxyl” as used herein alone or as part of another group, are used interchangeably and denote as used herein, alone or as part of another group denotes -COOH.
[0046] The term "cyano," as used herein, alone or as part of another group, denotes a group of formula -C=N.
[0047] As used herein, the term “conjugate” refers to a compound having a binding peptide that is linked to a chelating agent, such as a radionuclide chelating agent, either via direct bond or via a linker. For example, the chelating agent may be a compound capable of chelating radionuclides, such as203Pb and / or212Pb. The binding peptide may be capable of selectively binding to prostate-specific membrane antigen (PSMA).
[0048] The term “cyclization” as used herein, refers to the formation of one or more closed rings from a linear peptide or peptide segment by the introduction of a bond or a cyclization moiety.
[0049] The terms “cyclization moiety” and “cyclization group” are used interchangeably herein and refer to the residue of a chemical moiety7that facilitates cyclization of a linear peptide or peptide segment.
[0050] The term "cycloalkyl," as used herein, alone or as part of another group, denotes a cyclic saturated monovalent bridged or non-bridged hydrocarbon radical of three to ten carbon atoms. Exemplary cycloalkyl moieties include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and bicyclo[2.2.1]heptyl. Unless specified otherwise, the cycloalkyl group may be substituted at one or more ring positions with hydroxyl, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkoxy, acyl, acyloxy, amino, aryloxy, carboxy, cyano, halogen, mercapto, oxo, nitro, thiol, sulfo, and the salts thereof.
[0051] As used herein, "cycloaliphatic" denotes a chain of 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms containing one or more optionally substituted cycloalkyl moieties that can be saturated or at least partially unsaturated (but not aromatic). The cycloalkyl moiety may be a part of a pendant
[0052] (or side) group attached to a chain of atoms
[0053]
[0054] wherein * denotes the point of attachment to the remainder of the molecule, or the chain atoms comprise two or more carbon
[0055] atoms of the cycloalkyl moiety (e.g.,
[0056]
[0057] ). Cycloaliphatic excludes aralkylene.
[0058] As used herein the term "‘derivative” includes any compound which has been chemically modified without substantially altering its functional character. For example, a derivative may substantially retain one or more characteristic properties of said compound.
[0059] As used herein, the term “diagnostic agent” includes an “imaging agent”. As such, a “diagnostic radionuclide” includes radionuclides that are suitable for use as imaging agents.
[0060] As used herein, the term “prostate-specific membrane antigen (PSMA)” is a type II membrane protein that can be characterized by the murine monoclonal antibody (mAb) 7E11-C5.3 and is expressed in all forms of prostate tissue, including carcinomas. The PSMA protein contains a binuclear zinc site and is active as a glutamate carboxy peptidase. (Davis et al, Crystal Structure of Prostate-Specific Membrane Antigen, a Tumor Marker and Peptidase, Proc. Natl. Acad. Sci.
[0061] 102(17) 5981-5986 (Apr 18, 2005)). PSMA can be characterized by the murine monoclonal antibody (mAb) 7E11-C5.3 and is expressed in all forms of prostate tissue, including carcinomas. Certain studies have found the PSMA protein to have a unique 3-part structure, including a 19-amino-acid internal portion, a 24-amino-acid transmembrane portion, and a 707-amino-acid external portion. The PSMA gene is located on the short arm of chromosome 11 in a region that is not commonly deleted in prostate cancer. (Chang, Overview of Prostate-Specific Membrane Antigen, Rev. Urol. 6 (Suppl 10): S13-S18 (2004)).
[0062] The terms "halo" and “halogen” as used herein, alone or as part of another group, are used interchangeably and denote halogen atoms such as fluorine, chlorine, bromine, or iodine atoms.The term "haloalkyl group" as used herein, alone or as part of another group, denotes groups wherein any one or more of the alkyl carbon atoms is substituted with halo as defined herein. Specifically encompassed are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups including perhaloalkyl. A monohaloalkyl group, for example, may have either an iodo, bromo, chloro or fluoro atom within the group. Dihalo and polyhaloalkyl groups may have two or more of the same halo atoms or a combination of different halo groups. " Lower haloalkyl group" encompasses groups having 1-6 carbon atoms. In some embodiments, lower haloalkyl groups have one to three carbon atoms. Examples of haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
[0063] The term “heteroacyl” as used herein, alone or as part of another group denotes an acyl group, -C(O)R group, wherein the R group can be an alkyl, aryl, or heterocyclo as defined herein, and further comprising a heteroatom such as one or more of N, S, and O wherein the heteroatom may be a part of a pendant (or side) group attached to a chain of atoms or may be a chain atom.
[0064] The term "heteroaliphatic" as used herein, alone or as part of another group, denotes a cyclic or acyclic chain of 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, more typically 1 to 10 carbon atoms, and most typically 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms that can be saturated or unsaturated (but not aromatic), containing one or more hctcroatoms, such as halogen, oxygen, nitrogen, sulfur, phosphorus, or boron. A hctcroatom atom may be a part of a pendant (or side) group attached to a chain of atoms (e.g., *-CH(OH)CH(NH2)-* wherein * denotes the point of attachment to the remainder of the molecule and the carbon atoms are member of a chain of atoms) or it may be one of the chain atoms (e.g., -ROR- or -RNHR-where each R is aliphatic). Heteroaliphatic encompasses heteroalkyl and heterocycloalkylene but does not encompass heteroaralkylene.
[0065] The term "hctcroalkyl" as used herein, alone or as part of another group, denotes an alkyl group substituted by one or more hetero atoms.
[0066] As used herein, "heteroalkylene" refers to a divalent, fully saturated heteroalkyl moiety. As used herein, "heteroaralkylene" denotes a chain of 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms that can be saturated or unsaturated, containing one or more heteroaryl moieties. The heteroaryl moiety may be a part of a pendant (or side) group attached to a chain of atoms (e.g.,
[0067]
[0068] wherein * denotes the point of attachment to the remainder of the molecule, or the
[0069] chain atoms comprise two or more carbon atoms of the heteroaiyl moiety (e.g.,
[0070]
[0071] The term "heteroatom" denotes an atom other than carbon and hydrogen. Typically, but not exclusively, heteroatoms are selected from the group consisting of halogen, sulfur, phosphorous, nitrogen, boron and oxygen atoms. Groups containing more than one heteroatom may contain different heteroatoms.
[0072] The terms “heterocyclic group”, “heterocyclic”, “heterocycle”, “heterocyclyl”, and “heterocyclo” as used herein, alone or as part of another group, are used interchangeably and refer to any mono-, bi-, or tricyclic, saturated or unsaturated, aromatic (heteroaryl) or non-aromatic ring having the number of atoms designated, generally from 5 to about 16 ring atoms, where the ring atoms are carbon and at least one heteroatom (nitrogen, sulfur or oxygen), for example, 1 to 4 heteroatoms. Heterocyclic groups include four to seven membered cyclic groups containing one, two or three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Typically, a 5 -membered ring has 0 to 2 double bonds and 6- or 7-membered ring has 0 to 3 double bonds. The nitrogen or sulfur heteroatoms may optionally be oxidized (e.g., SO, SO2), and any nitrogen heteroatom may optionally be quaternized. Particular non-aromatic heterocycles are morpholinyl (morpholino), pyrrolidinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, 2,3-dihydrofuranyl, 2H-pyranyl, tetrahydropyranyl, thiiranyl, thietanyl, tetrahydrothietanyl, aziridinyl, azetidinyl, 1 -methyl-2-pyrrolyl, piperazinyl and piperidinyl. Particular 5-membered heterocycles containing a sulfur or oxygen atom and one to three nitrogen atoms are thiazolyl, in particular thiazol-2-yl and thiazol-2-yl N-oxide, thiadiazolyl, in particular l,3,4-thiadiazol-5-yl and l,2,4-thiadiazol-5-yl, oxazolyl, for example oxazol-2-yl, and oxadiazolyl, such as 1,3,4-oxadiazol-5-yl, and l,2,4-oxadiazol-5-yl. Particular 5-membered ring heterocycles containing 2 to 4 nitrogen atoms include imidazolyl, such as imidazol-2-yl; triazolyl, such as l,3,4-triazol-5-yl; l,2,3-triazol-5-yl, l,2,4-triazol-5-yl, and tetrazolyl, such as lH-tetrazol-5-yl. Particular benzofused 5-membered heterocycles are benzoxazol-2-yl, benzthiazol-2-yl and benzimidazol-2-yl. Particular 6-membered heterocycles contain one to three nitrogen atoms and optionally a sulfur or oxygen atom, for example pyridyl, such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl; pyrimidyl, such as pyrimid-2-yl and pyrimid-4-yl; triazinyl, such as l,3,4-triazin-2-yl and l,3,5-triazin-4-yl;pyridazinyl, in particular pyridazin-3-yl, and pyrazinyL The pyridine N-oxides and pyridazine N- oxides and the pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the 1,3,4-triazin-2-yl groups, are a particular group. Unless specified otherwise, the heterocyclo group may be substituted at one or more ring positions with hydroxyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, acyl, acyloxy, amino, aryloxy, carboxy, cyano, halogen, mercapto, oxo, nitro, thiol, sulfo, and the salts thereof.
[0073] As used herein, "heterocycloalkyl” denotes an alkyl radical, substituted by one or more heterocyclo moieties, wherein the linkage to the remainder of a moiety is through the alkyl radical.
[0074] As used herein, "heterocycloalkylene" denotes a chain of 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, and in some embodiments 1 to 4 carbon atoms containing one or more heterocyclic moieties that can be saturated or unsaturated (but not aromatic). The heterocyclic moiety may be a part of a pendant (or side) group attached
[0075] to a chain of atoms (e.g.,
[0076]
[0077] wherein * denotes the point of attachment to the remainder of the molecule, or the chain atoms comprise two or more carbon atoms of the heterocyclic moiety
[0078]
[0079] Heterocycloalkylene excludes heteroaralkylene.
[0080] The terms "hydrocarbon group" and "hydrocarbyl group" as used herein, alone or as part of another group, are used interchangeably and denote organic radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, and aiyl moieties. These moieties also include alkyl, alkenyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl and alkenaryl. Unless otherwise indicated, these moieties preferably comprise a chain of 1 to 25 carbon atoms, 1 to 20 carbon atoms, typically 1 to 12 carbon atoms, more typically 1 to 10 carbon atoms, and most typically 1 to 8 carbon atoms. Hydrocarbon groups may have a linear or branched chain structure. Typical hydrocarbon groups have one or two branches, typically one branch. Typically, hydrocarbon groups are saturated. Unsaturated hydrocarbon groups will typically have one or more double bonds.
[0081] As used herein, alone or as part of another group, "imine” denotes a functional group containing a carbon-nitrogen double bond (C=N).As used herein, lead (Pb) refers to the lead element and includes isotopes of both radioactive and observationally stable. The isotopes of Pb include, but are not limited to, Pb-196, Pb-197, Pb-198, Pb-199, Pb-200, Pb-201, Pb-202, Pb-203, Pb-204, Pb-205, Pb-206, Pb-207, Pb-208, Pb-209, Pb-210, Pb- 211, Pb-212, Pb-213, Pb-214, Pb-215, and Pb-216.
[0082] Similarly, as used herein, copper (Cu) refers to the copper element and includes isotopes of both radioactive and observationally stable. The isotopes of Cu include, but are not limited to, Cu-55, Cu-56, Cu-57, Cu-58, Cu-59, Cu-60, Cu-61, Cu-62, Cu-63, Cu-64, Cu-65, Cu-66, Cu-67, Cu-68, Cu-69, Cu-70, Cu-71, Cu-72, Cu-73, Cu-74, Cu-75, Cu-76, Cu-77, Cu-78, Cu-79, Cu-80, Cu-81, Cu-82, Cu-83, and Cu-84.
[0083] As used herein, “linker” refers to a chemical moiety that joins together certain moieties of the conjugate, such as a chelator (e.g. a lead specific chelating agent), a branching moiety Bp, and / or a targeting ligand (e.g., a PSMA targeted peptide). That is, the “linker” may correspond to the moiety “L” (Li, L2, and / or L3) described herein. Any suitable linker known to those skilled in the art in view of the present disclosure can be used in the invention. The linkers can contain, for example, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a substituted or unsubstituted aryl or heteroaryl, a polyethylene glycol (PEG) linker, a substituted or unsubstituted peptide linker, a sugar-based linker, or a cleavable linker, such as a disulfide linkage or a protease cleavage site such as valine-citrulline- p-aminobenzyl (PAB). For example, in certain embodiments, the linker can comprise a polyethylene glycol group that has been modified to covalently bond on cither end.
[0084] The term “nitro” as used herein, alone or as part of another group, denotes a group of the formula --NO2.
[0085] The terms “optional" and "optionally" as used herein means that the subsequently described circumstance may but need not occur, and that the description includes instances where the circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be further substituted. By way of further example, "optionally substituted alkoxy” means that the alkyl portion of the alkoxy group may, but need not be present, and the description includes embodiments in which the alkyl portion of the alkoxy group is substituted with one or more hetero atoms such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom or by a heterocyclo groups.
[0086] The term “optionally substituted” or “substituted” means that the referenced group is optionally substituted with one or more additional group(s), such as those individually andindependently selected from halogen, -CN, -NH2, -NH(alkyl), -N(alkyl)2, -OH, -CO2H, -CO2alkyl, -C(=O)NH2, -C(=O)NH(a Ikyl), — C(=O)N(alkyl)2, — S(=O)2NH2, — S(=O)2NH(alkyl), — S(=O)2N(alkyl)2, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone. In some other embodiments, optional substituents are independently selected from D, halogen, -CN, -NH2, -NH(CH3), -N(CH3)2, -OH, -CO2H, -CO2(Ci-C4alkyl), -C(=O)NH2, -C(=O )NH(Ci-C4alkyl), -C(=O)N(Ci-C4alkyl)2, -S(=O)2NH2, -S(=O)2NH(Ci-C4alkyl), -S(=O)2N(CI-C4alkyl)2, Ci-C4alkyl, C3-C6cycloalkyl, Ci-C4fluoroalkyl, Ci-C4heteroalkyl, Ci-C4alkoxy, Ci-C4fluoroalkoxy, -SCi-C4alkyl, -S(=O)Ci-C4alkyl, and -S(=O)2Ci-C4alkyl. In some embodiments, optional substituents are independently selected from D, halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -NH(cyclopropyl), -CH3, -CH2CH3, -CF3, -OC H3, and -OCF3. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, an optional substituent on an aliphatic carbon atom (acyclic or cyclic) includes oxo (=0). When indicating the number of substituents, the term “one or more” means from one substituent to the highest possible number of substitutions, i.e., replacement of one hydrogen up to replacement of all hydrogens by substituents.
[0087] As used herein, “peptide” means a small polypeptide having a size of 2 to 20 amino acid residues.
[0088] As used herein, “pharmaceutically acceptable” means suitable for in vivo use in a subject, and is not necessarily restricted to therapeutic use, but also includes diagnostic use. More generally, with respect to any pharmaceutical composition disclosed herein, non-limiting examples of suitable excipients include any suitable buffers, radioprotectants, salts, antioxidants, complexing agents, tonicity agents, cryoprotectants, lyoprotectants, suspending agents, emulsifying agents, antimicrobial agents, preservatives, chelating agents, binding agents, surfactants, wetting agents, non-aqueous vehicles such as fixed oils, or polymers for sustained or controlled release. See, for example, Berge et al. 1977. (J. Pharm Sci. 66:1-19), or Remington-The Science and Practice of Pharmacy, 21st edition (Gennaro et al editors. Lippincott Williams & Wilkins Philadelphia), each of which is incorporated by reference in its entirety.
[0089] The terms “polyethylene glycol linker,” “polyethylene glycol moiety” and “polyethylene glycol segment” are used interchangeably herein and denote a divalent chain of 1-10 ethylene oxide units, i.e., -(CH2CH2O)n- where n is 1-10The term “polypeptide” includes any polymer of amino acids, or amino acid residues connected together via amide bonds.
[0090] The term "polypeptide sequence” refers to a series of amino acid residues which physically comprise a polypeptide.
[0091] The term “protein” as used herein denotes a macromolecule comprising one or more polypeptides or polypeptide sequences, such as, for example, a naturally occurring or synthetic protein.
[0092] As used herein, the term “radionuclide” or “radioisotope” includes, but is not limited to, an alpha emitting radionuclides, beta-emitting radionuclides, and / or gamma-emitting radionuclides, such as, e.g., any one of Y-86, Y-90, Lu-177, Re-186, Re-188, Sr-89, Sm-153, Ac-225, Bi-213, Po-213, Bi-212, Ra-223, Ra-224, Th-227, Tb-149, Ga-67, Ga-68, Cu-64, Cu-67, Zr-89, Cs-137, Pb-203, Pb-212, and Pd-103, among others. For example, lead radionuclides can include any of Pb-196, Pb-197, Pb-198, Pb-199, Pb-200, Pb-201, Pb-202, Pb-203, Pb-204, Pb-205, Pb-206, Pb-207, Pb-208, Pb-209, Pb-210, Pb- 211, Pb-212, Pb-213, Pb-214, Pb-215, and Pb-216. Copper radionuclides can include any of Cu-55, Cu-56, Cu-57, Cu-58, Cu-59, Cu-60, Cu-61, Cu-62, Cu-63, Cu-64, Cu-65, Cu-66, Cu-67, Cu-68, Cu-69, Cu-70, Cu-71, Cu-72, Cu-73, Cu-74, Cu-75, Cu-76, Cu-77, Cu-78, Cu-79, Cu-80, Cu-81, Cu-82, Cu-83, and Cu-84. As used herein, the expressions “XE” and “E-x”, where “E” represents the element and “x” represents the particular elemental isotope, are equivalent and have the same meaning. For example, “xPb” and “Pb-x” (and “lead-x”) are equivalent and have the same meaning, such that “203pb” is equivalent to “Pb-203” (and to “lead-203”), and “212pb” is equivalent to “Pb-212” (and “lead-212”).
[0093] As used herein, the term “divalent radioisotope” refers to a radioactive isotope that typically forms ions with a charge of +2 (divalent cations) or sometimes -2 (divalent anions). Divalent radioisotopes are often used in labeling techniques, where they are attached to proteins or antibodies to track their movement or location in the body. Some common divalent cations used in radioimaging include, but not limited to, barium (Ba), calcium (Ca), cobalt (Co), copper (Cu), gallium (Ga), lead (Pb), radium (Ra), and strontium (Sr).
[0094] As used herein, the term “radiopharmaceutical” refers to a compound that is labeled with a radionuclide and is suitable for medical purposes, including treatment and diagnostic purposes, such as treatment of a disease state, including cancer (a radiotherapeutic), or diagnostic or imaging applications (a radiodiagnostic).As used herein, the terms “salt” and “solvate” have their usual meaning in chemistry. As such, when the compound is a salt or solvate, it is associated with a suitable counter-ion. It is well known in the art how to prepare salts or to exchange counter-ions. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of a suitable base (e.g. without limitation, Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are generally carried out in water or in an organic solvent, or in a mixture of the two. Counter-ions may be changed, for example, by ion-exchange techniques such as ionexchange chromatography. All zwitterions, salts, solvates and counter-ions are intended, unless a particular form is specifically indicated. In certain embodiments, the salt or counter-ion may be pharmaceutically acceptable, for administration to a subject.
[0095] As used herein, “selective binding” refers to a binding peptide or conjugate comprising the binding peptide that is capable of binding a cellular target with sufficient affinity such that the binding peptide and / or conjugate is useful as a diagnostic and / or therapeutic agent with respect to the target.
[0096] The term “subject” refers to an animal (e.g. a mammal or a non-mammal animal). The subject may be a human or a non-human primate. The subject may be a laboratory mammal (e.g., mouse, rat, rabbit, hamster and the like). The subject may be an agricultural animal (e.g., equine, ovine, bovine, porcine, camelid and the like) or a domestic animal (e.g., canine, feline and the like). In some embodiments, the subject is a human.
[0097] As used herein, a “target” may be prostate-specific membrane antigen (PSMA), which may be overexpressed in certain types of cancers, and may also be used as a marker for pro-tumorigenic stroma. In one embodiment, the extent of binding of the binding peptide and / or conjugate to an unrelated target is less than about 10% of the binding of the binding peptide and / or conjugate to its target as measured, e.g., by a radioimmunoassay. A “target selective” binding peptide, as used herein, is one that specifically binds to the target with sufficient specificity and affinity to be useful in targeting a therapeutic, targeting diagnostic, or method of detecting the target in a biological sample or a tissue from a subject. In some embodiments, binding peptide and / or conjugate, has a dissociation constant (KD) of < 1 pM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10-6M or less, e.g., from 10-6M to IO10M, e.g., from IO-8M to 1013M).
[0098] The term “therapeutically effective amount” as used herein to refer to an amount effective at the dosage and duration necessary to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary depending on factors such as the individual'scondition, age, sex, and weight, and the ability of the protein to elicit the desired response of the individual. A therapeutically effective amount can also be an amount that exceeds any toxic or deleterious effect of the composition that would have a beneficial effect on the treatment.
[0099] The term “thiol” as used herein, alone or as part of another group, denotes a group of the formula -SH.
[0100] As used herein, the terms “treat”, “treatment”, “therapeutic” and the like include ameliorating symptoms, reducing disease progression, improving prognosis and reducing recurrence.
[0101] The term “unsubstituted” means that the specified group bears no substituents.
[0102] It is understood that the disclosure of a compound herein encompasses all stereoisomers of that compound. As used herein, the term "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations. Stereoisomers include enantiomers and diastereomers.
[0103] The terms "racemate" or "racemic mixture" refer to a mixture of equal parts of enantiomers. The term "chiral center" refers to a carbon atom to which four different groups are attached. The term "enantiomeric enrichment" as used herein refers to the increase in the amount of one enantiomer as compared to the other.
[0104] It is appreciated that to the extent compounds of the present disclosure have a chiral center, they may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present disclosure encompasses any racemic, optically-active, diastereomeric, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the disclosure, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).
[0105] Radiopharmaceutical Conjugates
[0106] Embodiments of the present disclosure provide a conjugate that is capable of binding to PSMA, for example in humans and mice, and may thereby release radiation to targeted cancer cells and other cells (c.g., tumor stromal cells) in the tumor microenvironment. In accordancewith aspects of the present disclosure, a chelator (A) is attached to a PSMA targeted peptide (Tj, T2) that contains a linear or cyclic peptide, optionally via one or more linkers (that is, Li, L2, L?,) connecting through a branching moiety Bpaccording to the general formula
[0107] ZL — Ti
[0108]
[0109] , where each of Li, L?, and I..3 comprise a linker or a bond connecting the chelator to the PSMA targeted peptides. The conjugate can thereby bind to PSMA and release radiation at the tumor site.
[0110] According to one embodiment, the present disclosure provides a conjugate according to Formula 1 below,
[0111]
[0112] Formula 1
[0113] wherein
[0114] Li, L2 and L3 are independently a linker or a bond;
[0115] Ti and T2 are independently a PSMA targeted peptide; and
[0116] Bpis a branching moiety that connects Ti, T2 and chelator A.
[0117] In one embodiment, the conjugate further comprises a radioisotope that is coordinated by chelator A. Tn this embodiment, the conjugate corresponds to Formula 1 A below,
[0118]
[0119] wherein
[0120] Li, L2 and L3 are independently a linker or a bond;
[0121] Ti and T2 are independently a PSMA targeted peptide;
[0122] Bpis a branching moiety, and
[0123] M is a radionuclide.
[0124] For example, in one such embodiment M is a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, M is203Pb or212Pb. By way of further example, in one such embodiment, M is64Cu or67Cu. In addition, in one such embodiment Bpis alkyl (e.g., a carbon atom), carbocyclic or heterocyclic.
[0125] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 2 below,
[0126]
[0127] Formula 2
[0128] wherein Li, L2 and L3 are independently a linker or a bond; and T 1 and T2 are independently a prostate-specific membrane antigen (PSMA) targeted peptide. For example, in one suchembodiment the conjugate corresponds to Formula 2, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0129] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 3 below,
[0130]
[0131] Formula 3
[0132] wherein Li, L2 and L3 are independently a linker or a bond; Ti and T2 are independently a prostate-specific membrane antigen (PSMA) targeted peptide; and ring D is a cyclic moiety (e.g., carbocyclic or heterocyclic) that connects Ti, T2, and chelator A. For example, in one such embodiment the conjugate corresponds to Formula 3, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0133] In one embodiment, ring D, such as in Formula 3, is an optionally substituted, 5 to 10-membered carbocycle or heterocycle, and which may be aromatic or non-aromatic. In certain embodiments, ring D is selected from the group consisting of 5 -membered heterocyclic rings such as pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, furan, and thiophene. In certain embodiments, ring D is selected from the group consisting of 6-membered carbocyclic and heterocyclic rings such as benzene, pyridine, pyran, pyrimidine, pyridazine, pyrazine, piperazine, thiazine and oxazine. In other embodiments, ring D is selected from fused heterocycles having 9 or more ring atoms such as indole, isoindole, quinoline, isoquinoline,purine, naphthalene, purine, and chroman. According to certain embodiments, the groups connecting the ring D to Li, L2 and L3 may be in the ortho, meta, or para position with respect to one another.
[0134] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 4 below,
[0135]
[0136] wherein Li, L2 and L3 are independently a linker or a bond; and Bpis a branching moiety that connects Li, L2 and L3. For example, in one such embodiment the conjugate corresponds to Formula 4, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0137] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 5 below,
[0138]
[0139] wherein Li, L2 and L3 are independently a linker or a bond. For example, in one such embodiment the conjugate corresponds to Formula 5, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0140] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 6 below,
[0141]
[0142] wherein Li, L2 and L3 are independently a linker or a bond; and ring D is a carbocyclic or heterocyclic moiety that connects Li, L2, and L3. For example, in one such embodiment the conjugate corresponds to Formula 6, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0143] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 7 below,
[0144]
[0145] Formula 7
[0146] wherein the chelator A optionally coordinates a radioisotope, such as a radioisotope of lead or copper. For example, in one such embodiment the conjugate corresponds to Formula 7, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0147] According to one embodiment, the conjugate of the present disclosure corresponds to Formula 8 below,
[0148]
[0149] Formula 8
[0150] wherein the chelator A optionally coordinates a radioisotope, such as a radioisotope of lead or copper. For example, in one such embodiment the conjugate corresponds to Formula 8, and chelator A coordinates a radionuclide, M, e.g., a divalent radionuclide such as a radionuclide of copper or lead. By way of further example, in one such embodiment, the coordinated radionuclide is203Pb or212Pb. By way of further example, in one such embodiment, the coordinated radionuclide is64Cu or67Cu.
[0151] Target
[0152] Prostate-specific membrane antigen (PSMA) is a biomarker that is overexpressed on prostate cancer. PSMA is over-expressed in the malignant prostate tissues when compared to other organs in the human body such as kidney, proximal small intestine, and salivary glands. PSMA is also expressed on the neovasculature within many non-prostate solid tumors, including lung, colon, breast, renal, liver and pancreatic carcinomas, but is typically not overexpressed on normal vasculature. PSMA is also expressed minimally in brain. PSMA is a type II cell surface membrane-bound glycoprotein with -110 kD molecular weight, any has been characterized as including an intracellular segment (amino acids 1-18), a transmembrane domain (amino acids 19-43), and an extensive extracellular domain (amino acids 44-750). While the functions of the intracellular segment and the transmembrane domains are currently believed to be insignificant, the extracellular domain is involved in several distinct activities. For example, PSMA plays a role in the central nervous system, where it metabolizes N-acetyl-aspartyl glutamate (NAAG)into glutamic and N-acetyl aspartic acid. (Sedak et al., Parallel Metabolomics and Lipidomics of a PSMA / GCPTI Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition, ACS Chemical Neuroscience, Vol. 15, issue 7 (2024)). PSMA also plays a role in the proximal small intestine where it removes γ-linked glutamate from poly-y-glutamated folate and a-linked glutamate from peptides and small molecules. (Ghosh et al., Tumor Target Prostate Specific Membrane Antigen (PSMA) and its Regulation in Prostate Cancer. J Cell Biochem. 91 (3):528- 39 (2004)). Unlike many other membrane-bound proteins, PSMA typically undergoes rapid internalization into the cell in a similar fashion to cell surface bound receptors like vitamin receptors. PSMA is believed to be internalized through clathrin-coated pits and subsequently can either be recycled to the cell surface or go to lysosomes. (Kessel et al., Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression:
[0153] Implications for Patient Management, Cancers, 73(14), 3556 (2021)). Accordingly, diagnostic, imaging, and therapeutic agents can be targeted to PSMA for delivery into PSMA expressing cells, such as prostate cancer cells.
[0154] Prostate-Specific Membrane Antigen (PSMA)-Targeted Peptide
[0155] According to certain embodiments, the PSMA-targeted peptide (Tj, Tj) comprises a sequence of amino acid residues that provide for binding to the PSMA target. According to one embodiment, all of the amino acid residues may be L-amino acids. According to another embodiment, all of the amino acid residues may be D-amino acids. According to yet another embodiment, the sequence may comprise a mixture of some L- and some D- amino acids. One or more of the amino acids may also be beta-homo amino acids. For reference, a list of naturally occurring amino acids and their three and one letter abbreviations is provided in the table below.
[0156]
[0157]
[0158] According to certain embodiments, the PSMA-targeted peptide (Ti, T2) comprises a urea or thiourea of lysine and an amino acid, or one or more deri vatives thereof, including, but not limited to ureas or thioureas of lysine and aspartic acid, or glutamic acid, or homoglutamic acid.
[0159] According to certain embodiments, the PSMA-targeted peptide (T j, T?;) comprises a urea or thiourea of lysine, and glutamic acid, or a derivative thereof. For example, the PSMA peptide can comprise the peptide sequence Lys-Urea-Glu
[0160] According to certain embodiments, the PSMA-targeted peptide (Tt, T?) comprises the residue of:
[0161]
[0162] Linkers (L)
[0163] In certain embodiments, the linkers ( e., Lt. L-_>, and / or Ls) are chemical linkers that connect different moieties of the conjugate. For example, Li and Lc are inserted into aposition between the PSM A-targeted peptide (Ti. T?) and the branching moiety (Bp), while L3 is inserted into a position between the branching moiety (Bp) and the chelator ( A) that is used to radiolabelthe composition using radionuclides for diagnostic imaging and / or therapy. According to certain embodiments, the linkers may improve the retention of the composition on the cell surface. According to certain embodiments, the linkers may improve the internalization of the composition into cells. According to certain embodiments, the linkers may improve the retention of the composition in tumors for more precise delivery of radiation to the cancerous tissue.
[0164] The linkers can contain, for example, a substituted or unsubstituted alkyl, a substituted or unsubstituted heteroalkyl moiety, a substituted or unsubstituted aryl or heteroaryl, a polyethylene glycol (PEG) moiety, a substituted or unsubstituted peptide moiety, a sugar-based moiety, or a cleavable moiety, such as a disulfide linkage or a protease cleavage site such as valine-citrulline-p-aminobenzyl (PAB). For example, in certain embodiments, the linkers can comprise a polyethylene glycol moiety. In some embodiments, the linkers comprise substituted or unsubstituted C1-C30 alkylene.
[0165] In one embodiment, one or more of the linkers may comprise a chain of 5 to 20 atoms selected from the group consisting of nitrogen, oxygen, sulfur and optionally substituted carbon atoms, wherein the carbon atoms are optionally substituted with oxo (=0), optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aralkyl, or optionally substituted heteroaralkyl. Examples of optionally substituted heteroalkyl can include -CH2-pyridinyl, -(CFE -pyridinyl, and -(CFb -imidazoyl.
[0166] In some embodiments, one or more of the linkers may comprise one or more of substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In some embodiments, one or more of the linkers can comprise one or more amino acid residues. In some embodiments, one or more of the linkers comprise 1 to 3, 1 to 5, 1 to 10, 5 to 10, or 5 to 20 amino acid residues. In some embodiments, one or more of the linkers comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid resid ues. In sonic embodiments, one or more of the linkers comprise 1 to 5 amino acid residues. For example, the linkers can comprise one or more lysine (K) residues, serine (S) residues, phenylalanine (F) residues, and combinations thereof. In some embodiments, one or more amino acids of the linkers are unnatural amino acids or other groups such as cysteamine, and / or the amino acid may have a modified N or C terminus.
[0167] According to certain embodiments, the linkers can attach to a ring D comprising a cyclic moiety, c.g. in Formula 3 above. In some embodiments, one or more of the linkers arc atached via a peptide bond to the ring D. The linkers can be bonded to the ring D through a chemicallyreactive group. Exemplary chemically reactive groups include, but are not limited to, a free amino, imino, hydroxyl, thiol or carboxyl group (e.g., to the N- or C-terminus, to the epsilon amino group of one or more lysine residues, the free carboxylic acid group of one or more glutamic acid or aspartic acid residues, or to the sulfhydryl group of one or more cysteinyl residues). Exemplary methods for attaching the linkers includes carbodiimide reaction, reactions using bifunctional agents such as dialdehydes or imidoesters, Schiff base reaction, Suzuki-Miyaura cross-coupling reactions, isothiocyanates as coupling agents, and click chemistry. In one embodiment, one or more of the linkers can be formed from a benzyl isothiocyanate moiety, which can be reacted with another part of the linkers or the ring segment D to form benzyl thiourea linkage. In one embodiment, one or more of the linkers comprises a benzyl thiourea moiety bonded to a polyethylene glycol moiety that is formed by the reaction of benzyl isothiocyanate group with an amino-polyethylene glycol-acid which may have the formula NH2-(CH2CH2-O)n-(CH2)m-C(=O)OH, where n and m are 1-10.
[0168] According to certain embodiments, the linkers may have a length that is selected to provide an appropriate distance between one or more of the binding peptides T;, T2and the chelator A. For example, according to certain embodiments, the linkers may each have 1 to 100 atoms, 1 to 60 atoms, 1 to 30 atoms, 1 to 15 atoms, 1 to 10 atoms, 1 to 5, or 2 to 20 atoms in length. In some embodiments, the linkers each have 1 to 10 atoms in length. For example, in such embodiments the atoms may be selected from the group consisting of nitrogen, oxygen, sulfur and optionally substituted carbon atoms, wherein the carbon atoms are optionally substituted with oxo (=0), optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aralkyl, or optionally substituted heteroaralkyl.
[0169] In some embodiments, one or more of the linkers comprise a polyethylene glycol segment, such as -(CH2CH2O)1-10-. For example, according to certain embodiments, one or more of the linkers can comprise a polyethylene glycol segment that is to provide for covalent bonding on the ends of the segment, such as amino-polyethylene glycol-acid, having from 1 to 10 PEG groups, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 PEG groups, such as 2 PEG groups, and having the residue of an acid group on one end of the segment and an amino group on the other (e.g. derived from NH2-(CH2CH2-O)n-(CH2)m-C(=O)OH, where n and m are 1-10). The one or more linkers formed from the modified PEG may comprise the segment -NH-(CH2CH2O)n-(CH2)m-C(=O)-, where n and m are 1-10, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In one embodiment, m is 1-2, and n is 1-10, such as 1-8, 1-6, 1-4, 2-4, and even 4.In some embodiments, one or more of the linkers are independently derived from a carboxylic acid, such as a fatty acid, which may be a straight chain, optionally saturated fatty acid. The carboxylic acid may be a C2 to a C10 straight chain carboxylic acid, optionally a C4 to a Cs straight carboxylic acid, such as hexanoic acid. The acid may be modified to provide for covalent bonding on either end of the acid. This can be achieved by including a free amino, imino, hydroxyl,, thiol or carboxyl group on each end. In some embodiments, one or more of the linkers are independently derived from a compound comprising the formula R33(CH2)n(C:=:O)OH, wherein n is 1 to 10, such as 1-10, 1-8, or 1-6, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and R33 is a group that is able to form a covalent bond with another part of the conjugate, such as the chelator, PSMA targeted peptide, or another segment of a linker, such as for example any of a free amino, imino, hydroxyl, thiol or carboxyl group. In one embodiment, one or more of the linkers are formed from a compound comprising the formula NH2-(CH2)nC(=O)OH, wherein n is 1 to 12, 1-10, 1-8, or 1-6, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 such as for example a 6-amino hexanoic acid (6-AHA) or 12-amino-dodecanoic acid (12-ado). The one or more linkers thus formed comprise the formula -NH-(CH2)nC(=O)-, where n is 1-12, 1-10, 1-8, or 1-6, such as any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11. According to some embodiments, one or more of the linkers comprise the residue of one or more amino-polyethylene glycol-acid and / or the compound having the formula R 3(CH2)n(CK))OH, such as derived from NH2(CH2)nC(=O)OH, in combination with one or more amino acid residues.
[0170] In some embodiments, one or more of the linkers comprise an aliphatic chain modified with a thiol moiety on one end, and an amine group on the other, such as the residue of a compound NH2-(CH2)n-SH, where 11 is from 1 to 6, such as 2-4, and even 2 (as in the case of cysteamine). The linkers thus formed may have the formula -NH(CH2)nS-, where n is from 1 to 6, such as 2-4, and even 2.
[0171] In some embodiments, one or more of the linkers comprise a click chemistry residue. In some embodiments, one or more of the linkers are attached to the binding peptide, to the chelator, or both via click chemistry, thereby forming a click chemistry residue. For example, the binding peptide can comprise an azide group that reacts with an alkyne moiety of the linker. For another example, the peptide can comprise an alkyne group that reacts with an azide of the linker. The chelator and the linker can be attached similarly. In some embodiments, one or more of the linkers comprise an azide moiety, an alkyne moiety, or both. In some embodiments, the linker comprises a triazole.In some embodiments, one or more of the linkers comprise substituted or unsubstituted C1-C30 alkylene, C1-C12 alkylene, Ci-Cs alkylene, Ci-Ce alkylene, or C2-C6 alkylene. Tn some embodiments, one or more of the linkers comprise C2-C6 alkylene. In some embodiments, the linkers comprise C4-C6 alkylene.
[0172] In some embodiments, one or more of the linkers comprises an amino acid residue, such as for example any of lysine, threonine, phenylalanine, and glycine.
[0173] In certain embodiments, one or more of the linkers comprise hydrophobic linkers consisting of an aliphatic carbon chain that connects the chelator to the peptide backbone. In certain embodiments, one or more of the linkers comprise hydrophilic linkers that include heteroatom substitutions in the aliphatic chain that connects the chelator to the peptide backbone. In certain embodiments, one or more of the linkers are a mixture of hydrophilic and hydrophobic entities. In certain embodiments, one or more of the linkers comprise an aliphatic (ALP) moiety of 2 or 4 carbons. In certain embodiments, one or more of the linkers are derived from a mixture of piperidine (PIP) and one or more amino acids. Tn certain embodiments, the linkers comprise a mixture of piperazine and one or more amino acids. In certain embodiments, one or more of the linkers are derived from moieties including benzene and one or more amino acids. In certain embodiments, one or more of the linkers may be “cleavable” linkers derived from a mixture of natural amino acids such as Phe, Met, He that can be cleaved in kidney brush boarder membrane to facilitate the clearance through kidneys. According to one embodiment, one or more of the linkers can be derived from any one or combination of 2 or more residues of lysine, serine, phenylalanine, cysteamine, 6-amino hexanoic acid; benzyl-isothiocyanate, 12-amino-dodecanoic acid, and amino-polyethylene glycol-acid (having from 2-4 polyethylene glycol groups).
[0174] Other linkers are known in the art. See, e.g., Bandari R P, Jiang Z, Reynolds T S, Bemskoetter N E, Szczodroski A F, Bassuner K J, Kirkpatrick D L, Rold T L, Sieckman G I.., Hoffman T J, Connors J P, Smith C J. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr / PSMA) of prostate cancer. Nucl Med Biol. 2014; 41 (4):355-363. Doi: 10.1016 / j.nucmedbio.2014.01.001. PubMed PMID: 24508213: PMC1D: PMC4O41584; Dumont R A, Tamma M, Braun F, Borkowski S, Reubi J C, Maecke H, Weber W A, Mansi R. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med.
[0175] 2013; 54(5):762-769. Doi: 10.2967 / jnumed.112.112169. PubMed PMID: 23492884; Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi J C, Maecke H R. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of68Ga- and 64Cu-labeled peptides for PET imaging. J Nucl Med. 2014; 55(10): 1719-1725. Doi:
[0176] 10.2967 / jnunied.114.141242. PubMed PMID: 25146125; Jamons M, Tamma M L, Gourni E, Waser B, Reubi J C, Maecke H R, Mansi R. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. Nucl Med Biol. 2014: 41(6):464-470. Doi: 10.1016 / j.nucmedbio.2014.03.014. PubMed PMID: 24780298; Mansi R, Abiraj K, Wang X, Tamma M L. Gourni E, Cescato R, Berndt S, Reubi J C, Maecke H R. Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRPR) positive tumors. J Med Chem. 2015; 58(2):682-691. Doi: 10.1021 / jm5012066. Pub ed PMID: 25474596; Pan D, Xu Y P, Yang R H, Wang L, Chen F, Luo S, Yang M, Yan Y. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids. 2014; 46(6): 1481 -1489. Doi: 10.1007 / s00726- 014-1718-y. PubMed PMID: 24633452; Stott Reynolds T J, Schehr R, Liu D, Xu J, Miao Y, Hoffinan T J, Rold T L. Lewis M R, Smith C J. Characterization and evaluation of DOT A-conjugated BombesinfRGD-antagonists for prostate cancer tumor imaging and therapy. Nucl Med Biol. 2015; 42(2 ):99- 108. Doi: 10.1016 / j.nucmedbio.2014.10.002. PubMed PMID:
[0177] 25459113.
[0178] Additional exemplary linkers that are applicable to the conjugate disclosed lierein can be found, for example, in U. S. Patent No. 10,975,089, U. S. Patent Application Publication No. 20250011362, PCT Application Publication Nos: WO2013022797. WO2014078484A1, WO2015171792, WO2017116994, WO2018222778A1, WO2019075583, W02019165200, and WO2020229974. The relevant description on linkers in those documents are incorporated herein by reference.
[0179] In one embodiment, one or both of the linkers Li and L2 comprise a moiety corresponding to the following:
[0180]
[0181] wherein each W is independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl. For example, in one such embodiment W is the organic side chain of one of the 22 naturally occurring a-amino acids incorporated into proteins. By way of further example, in one such embodiment W is aralkyl or heterocycloalkyl. By way of furtherexample, in one such embodiment, linkers Li and L?_ may independently comprise any of the following segments:
[0182]
[0183] where n is 0 to 5, and each R is independently hydrogen, -OH, halo, alkyl, or -NH2.
[0184] In one embodiment, one or both of the linkers Li and L2 comprise the following:
[0185]
[0186] wherein Zi and Z2 are independently selected from the group consisting of (i) optionally substituted 5-6 membered carbocycle, (ii) optionally substituted 5-6 membered heterocycle, (iii) optionally substituted 9-10 membered carbocyclc, (iv) optionally substituted 9-10 membered heterocycle, and (v) optionally substituted anthracene or optionally substituted acridine, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl. In one embodiment, Zi and Z2 are independently selected from the group consisting of (i) optionally substituted 5-6 membered carbocycle, and (ii) optionally substituted 5-6 membered heterocycle, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl. In one embodiment, Zi and Z2 are independently selected from the group consisting of (i) optionally phenyl, optionally substituted pyridinyl, optionally substituted imidazoyl, and optionally substituted naphthyl, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl. In one embodiment, Zi and Z2are phenyl or naphthyl.According to one embodiment, Li and L2 are linkers that independently comprise one or more of the following segments,
[0187]
[0188]
[0189]
[0190] According to one embodiment, L3 is a linker comprising one or more of the following:
[0191]
[0192] wherein n is 1-10.
[0193] In one embodiment, L3 comprises a polyethylene glycol moiety, -(CFFCFbO)!!- wherein 11 is 1-10.
[0194] Chelators (A)
[0195] In certain embodiments, A is a chelator (also called a “chelating agent”). The chelator can be used to radiolabel the composition with radioisotopes, such as for example to provide for any of imaging, diagnostics and therapeutic treatment. For example, the chelator A may be radiolabeled with a radionuclide that is used for medical imaging, diagnosis and / or therapy of cancerous tumors, such as in the case of PSMA positive malignancies.For example, in some embodiments, the chelator A may be derived from (i.e. comprise the residue of) a lead specific chelator (PSC) having the following structure:
[0196]
[0197] According to certain embodiments, the linker L3 can be connected to the lead specific chelator by chemical reaction with any of the amide groups in the lead specific chelator.
[0198] According to one embodiment, a structure for the conjugate having a lead specific chelator that is conjugated to two PSMA-targctcd binding peptides (via a branching moiety, BP, and three linkers, Li, I..2, Li) is shown below.
[0199]
[0200] For example, in one embodiment, the structure for the conjugate having a lead specific chelator that is conjugated to two PSMA-targeted binding peptides can comprise the following:
[0201]
[0202] Formula 7
[0203] For another example, in one embodiment, the structure for the conjugate having a lead specific chelator that is conjugated to two PSMA-targeted binding peptides can comprise the following:
[0204]
[0205] According to certain embodiments, the conjugate described herein comprises a chelator that chelates a radionuclide, and which may be a radionuclide that provides a therapeutic effect, and / or that is useful for imaging and / or diagnosis. In some embodiments, the radionuclide comprises an alpha particle-emitting radionuclide. In other embodiments, the radionuclide comprises a beta particle emitting radionuclide. In other embodiments, the radionuclide comprises a gamma ray emitting radionuclide.
[0206] In some embodiments, the radionuclide is a therapeutic radionuclide selected from the group consisting of212Pb,67Cu,64Cu,89Zr,90Y,109Pd, "'Ag,149Pm,153Sm,166Ho,99mTc,67Ga,68Ga,11'in,90Y,177Lu,186Re,188Re,197Au,198Au,199Au,105Rh,165Ho,161Tb,149Pm,44Sc,47S c,70As,71AS,72AS,73As,74AS,76AS,77AS,212Pb,212Bi,213Bi,225Ac, "7mSn,67Ga,201Tl,123I,131I,160Gd,148Nd,89Sr, and211At. In some embodiments, radionuclide is selected from the group consisting of diagnostic radionuclides43Sc,44Sc,31Mn,64Cu,67Ga,68Ga,86Y,89Zr,99mTc,18F,76Br,77Br,11'in,123I,124I,12’1,152Tb, and2O3Pb. In certain embodiments, the radionuclide is selected from the group consisting of therapeutic radionuclides47Sc,67Cu,89Sr,90Y,13'l,153Sm,149Tb,161Tb,177LU,186Re,188Re,211At,212Pb,212Bi,223Ra,224Ra,225Ac,226Th, and227Th.
[0207] In certain embodiments, the radionuclide is In-111, Pb-203; Cu-64, Ga-68, Zr-89, or other medical radionuclide used for imaging. The radionuclide for imaging may be Pb-203 or CU-64.
[0208] In certain embodiments, the radionuclide is Cu-67, Y-90, Pb-212, Bi-212, Bi-213, At-211. Ac-225, Lu-177 or other medical radionuclide used to treat the cancerous tumors. The radionuclide for treating cancerous tumors may be Pb-212 or Cu-67.
[0209] In one embodiment, the radionuclide may be a lead radionuclide that is any selected from the group consisting of Pb-196, Pb-197, Pb-198, Pb-199, Pb-200, Pb-201, Pb-202, Pb-203, Pb-205, Pb-209, Pb-210, Pb- 211, Pb-212, Pb-213, Pb-214, Pb-215, and Pb-216. According to certain embodiments, the lead radionuclide that is conjugated by the lead specific chelating moiety comprises any of Pb-203 or Pb-212. Pb-203 emits y-photons through electron capture, allowing detection with single-photon emission computed tomography (SPECT) for diagnostic imaging, whereas Pb-212 decays by emitting β-particles and a-particles suitable for delivering therapeutic doses of radiation to cancer cells.
[0210] In another embodiment, the radionuclide may be a copper radionuclide that is any selected from the group consisting of Cu-55, Cu-56, Cu-57, Cu-58, Cu-59, Cu-60, Cu-61, Cu-62, Cu-63, Cu-64, Cu-65, Cu-66, Cu-67, Cu-68, Cu-69, Cu-70, Cu-71, Cu-72, Cu-73, Cu-74, Cu-75,Cu-76, Cu-77, Cu-78, Cu-79, Cu-80, Cu-81, Cu-82, Cu-83, and Cu-84. According to certain embodiments, the copper radionuclide that is conjugated by the copper specific chelating moiety comprises any of Cu-64 or Cu-67.
[0211] According to one embodiment, a structure for conjugate having a lead specific chelator that is conjugated to two PSMA-targeted binding peptides, and having either a lead-203 (2O’Pb) or lead-212 (212Pb) radionuclide, is shown below.
[0212]
[0213] According to another embodiment, a structure for conjugate having a lead specific chelator that is conjugated to two PSMA-targeted binding peptides, and having either a lead-203 (20jPb) or lead-212 (2[2Pb) radionuclide, is shown below.
[0214]
[0215] Albumin Binding
[0216] In certain embodiments, an albumin-binding moiety is conjugated to the PSMA -targeted binding peptide Ti, T?, such as via any of the linkers Lj, Li and / or L, or via the ring D, to extend die biological half-life in circulation and to enhance die accumulation in tumor,
[0217] Ln certain embodiments, an albumin-binding moiety can be naphthalene-2-sulfonamide derivatives, Evans Blue derivatives, 4-(p-Iodophenyl)butyric acid derivatives, palmitic acid derivatives, and maleimide derivatives.
[0218] Pharmaceutical Formulation
[0219] The radiolabeled conjugates / radiopharmaceutical compounds described herein can be administered in a radiopharmaceutical formulation suitable for delivery to a subject, such as for example via intravenous, intramuscular, topical or subcutaneous administration, and may be in form of an aqueous solution (e.g. saline solution) containing the radiolabeled conjugate in a concentration sufficient for one or more of diagnostic and therapeutic purposes, as well as optional radioprotectants and / or oxidants, buffers, etc. The radiolabeled conjugate may be prepared in phosphate-buffered saline (PBS) with or without radioprotectants including any one or more of ascorbic acid, sodium acetate, gentisic acid, and ethanol, at concentrations that are suitable for human or animal use.According to certain embodiments, the conjugate may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the conjugate or its salts can be prepared in water, isotonic saline, phosphate-buffered saline (PBS), optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. In certain embodiments, the final solution contains ethanol from 0 to 20% v / v. In certain embodiments, the final pH of the solution is 2-9. In certain embodiments, the conjugate is administered with additional amino acids to reduce the uptake of radioactive compound in kidneys. In certain embodiments, the amino acids are lysine and arginine. According to certain embodiments, a preparation containing the conjugate contains a preservative excipient to prevent the growth of microorganisms.
[0220] According to one embodiment, a formulation of the conjugate described herein may be provided in lyophilized form, such as for example for storage of the conjugate prior to labelling and administration. For example, an aqueous solution of the conjugate may be prepared with additional formulation components such as buffers, radioprotectants, or other excipients, and the solution may be lyophilized (freeze dried) to provide for storage of the conjugate formulation. According to certain embodiments, the lyophilized formulation can be stored under vacuum or in an inert atmosphere. The lyophilized formulation can be reconstituted prior to administration, such as for example by combining with a sterile aqueous solution, to form a liquid composition. According to certain embodiments, an aqueous solution provided to reconstitute the lyophilized formulation may also optionally include components, such as any of buffers, radioprotectants, or other components to stabilize the composition, and / or to improve administration. According to certain embodiments, the reconstituted formulation can be combined with a radionuclide selected to provide therapeutic treatment and / or to provide for diagnosis / imaging of tissues have elevated PSMA expression. The radionuclide is chelated by the chelator of the conjugate, to provide the radiolabeled conjugate for administration to a subject. The formulations may also comprise a radioprotectant, such as sodium ascorbate.
[0221] According to certain embodiments, pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the conjugate which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols,and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0222] According to certain embodiments, sterile injectable solutions are prepared by incorporating the conjugate in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying techniques (lyophilization), which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile- filtered solutions. According to certain embodiments, for topical administration, the conjugates may be applied in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
[0223] In one embodiment, the present disclosure provides an aqueous formulation comprising the conjugate disclosed herein and as radiolabeled with a lead radioisotope, wherein the formulation comprises a buffer and optionally further comprises a stabilizer selected from the group consisting of ascorbic acid, sodium acetate, gentisic acid, and ethanol. In some embodiments, the lead radioisotope is203Pb (Pb-203), and is provided in the formulation in an amount sufficient to provide a dosage of 50-1000 MBq, 100-700 MBq, and / or 150-500 MBqper dose. In some embodiments, the lead radioisotope is2l2Pb (Pb-212), and is provided in the formulation in an amount sufficient to provide a dosage of 18-3700 MBq, 37-1850 MBq, 50-370 MBq, and / or 74- 185 MBq per dose.
[0224] According to certain embodiments, useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol / glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads.used to impregnate bandages and other dressings, or sprayed onto the affected area using pump¬ type or aerosol sprayers. According to certain embodiments, thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
[0225] The dosage of the conjugates may vary depending on age, weight, and condition of the subject. Treatment may be initiated with small dosages containing less than optimal doses, and increased until a desired, or even an optimal effect under the circumstances, is reached.
[0226] According to certain embodiments, the dosage may be about 450-600 nig / kg / day in patients weighing less than 20 kg, or 9.9-13.0 g / n / day in larger patients. Higher or lower doses, however, are also contemplated and are, therefore, within the confines of this invention. A medical practitioner may prescribe a small dose and observe the effect on the subject’s symptoms. Thereafter, they may increase the dose if suitable. In general, the conjugates may be administered at a concentration that affords effective results without causing any unduly harmful or deleterious side effects, and may be administered either as a single unit dose, or if desired in convenient subunits administered at suitable times.
[0227] According to certain aspects, a pharmaceutical composition is formulated to be compatible with its intended route of administration. For example, the conjugate may be introduced directly into the cancer of interest via direct injection. Additionally, examples of routes of administration include oral, parenteral, e.g., intravenous, slow' infusion, intradermal, subcutaneous, oral (e.g., ingestion or inhalation), transdermal (topical), transmucosal, and rectal administration. Such compositions can comprise the conjugate and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration, and a dietary food-based form. The use of such media and agents for pharmaceutically active substances is well known in the art and food as a vehicle for administration is well known in the art.
[0228] According to certain embodiments, solutions or suspensions can include the following components: a sterile diluent such as water for injection, saline solution (e.g., PBS), fixed oils, a polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), glycerine, or other synthetic solvents; antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like; antioxidants such as ascorbic acid,gentisic acid, sodium bisulfite; chelating agents such as EDTA, DTPA, DMSA, DMPS; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.
[0229] Prolonged administration of the injectable compositions can be brought about by including an agent that delays absorption. Such agents include, for example, aluminum monostearate and gelatin. The parenteral preparation can be enclosed in ampules, disposable syringes, or multiple dose vials made of glass or plastic.
[0230] According to certain aspects, it may be advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for an individual to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The dosage unit forms of the invention are dependent upon the amount of a compound necessary to produce the desired effect(s). The amount of a compound necessary can be formulated in a single dose, or can be formulated in multiple dosage units. Treatment may require a one-time dose, or may require repeated doses.
[0231] Diagnostic and Therapeutic Uses
[0232] Embodiments of the present disclosure provide methods of targeting a prostate-specific membrane antigen (PSMA) comprising administering a radiolabeled compound comprising the PSMA-targeted conjugate as discussed above.
[0233] Embodiments of the present disclosure further provide methods of imaging and / or diagnosing a subject having a disorder that is a result of or associated "with upregulated PSMA expression, the method comprising administering to the subject a radiolabeled compound comprising the prostate-specific membrane antigen (PSMA)-targeted conjugate discussed above, and imaging the subject. Thus, aspects of the present disclosure provide methods for imaging or diagnosing a cancer or tumor in a subject in need thereof, by administering a radiopharmaceutical comprising a radiolabeled conjugate described herein to the subject, and imaging tissue having the radiolabeled conjugate bound thereto. That is, when the radiolabeled conjugate is labeled withradioisotope that is suitable for imaging purposes, the conjugate can be administered to a subject and will accumulate at target sites for which the binding moiety is selective. Imaging techniques such as single photon emission computed tomography (SPECT) imaging or positron emission topography (PET) imaging can be performed to view the accumulation of the radiolabeled conjugate at target sites, which may be indicative of a location of cancerous cells, such as cancerous cells overexpressing PSMA.
[0234] According to certain aspects,203Pb (Pb-203) may be suitable for imaging processes such as SPECT, to provide for imaging and diagnosing of the presence or extent of cancer and / or tumors in a subject.
[0235] For example, in one embodiment, the present disclosure provides a method of imaging or diagnosing a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising administering the conjugate of any preceding claim, as radiolabeled with a lead radioisotope203Pb, to the subject, and imaging tissue having the radiolabeled conjugate compound bound thereto.
[0236] Furthermore, according to certain embodiments, a method of treating a subject having a disorder that is a result of or associated with upregulated PSMA expression can be provided in a subject in need thereof, the method comprising administering to the subject a radiolabeled compound comprising the prostate-specific membrane antigen (PSMA) -targeted conjugate discussed above.
[0237] Thus, the present disclosure provides methods of treatment of cancer in need thereof, by administering a radiopharmaceutical comprising a radiolabeled conjugate described herein to the subject, in therapeutically effective amounts that are sufficient to treat the subject. That is, when the radiolabeled conjugate is labeled with a radioisotope that is suitable for treatment purposes, the conjugate can be administered to a subject and will accumulate at target sites for which the binding moiety is selective, and which may be indicative of a location of cancerous cells, such as cancerous cells overexpressing PSMA, or stroma cells. The radiation emitted by the radiolabeled conjugate bound to the target site may provide a cell killing effect that is selective for the target cells, thereby providing treatment. PSMA.
[0238] According to certain aspects,212Pb (Pb-212) may be suitable for killing the cancer cells, to provide treatment of cancer and / or tumors in a subject.
[0239] For example, in one embodiment, the present disclosure provides a method of treating a subject suffering from a cancer associated with overexpression of prostate-specific membraneantigen (PSMA), the method comprising administering the conjugate of any preceding claim, as radiolabeled with a lead radioisotope212Pb, to the subject, in a dosage sufficient to kill tumor cells.
[0240] According to one embodiment, the present disclosure further provides a method of diagnosing and treating a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising: diagnosing the subject by administering the conjugate of any preceding claim to the subject, as radiolabeled with a lead radioisotope where203Pb, and imaging tissue having the radiolabeled conjugate compound bound thereto to diagnose the subject as being afflicted with the cancer, and treating the subject diagnosed as being afflicted by the cancer, by administering the conjugate of any preceding claim to the subject, as radiolabeled with a lead radioisotope212Pb, in a dosage sufficient to kill cancer cells.
[0241] In one embodiment, the tissue is imaged via single-photon emission computed tomography (SPECT) imaging, optionally in combination with computed tomography (CT) imaging.
[0242] According to certain embodiments, the cancer is associated with PSMA overexpression in the subject. For example, the cancer may be selected from the group consisting of prostate cancer, thyroid cancer, oral cancer, gastric cancer, colorectal cancer, lung cancer, breast cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, bladder cancer, glioblastoma, follicular lymphoma, brain tumors, multiple myeloma, hepatocellular carcinoma, osteosarcoma, hepatocellular cholangiocarcinoma, melanoma, thymoma type b2, GE junction adenocarcinoma, signet-ring cell carcinoma, GI stromal tumor, rectal adenocarcinoma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, and squamous cell carcinoma.
[0243] In one embodiment, the cancer is any of prostate cancer, breast cancer, renal cell carcinoma, and lung cancer.
[0244] In certain embodiments, the conjugate is administered intravenously or parenterally. In certain embodiments, the conjugate is administered in a single dose, hi certain embodiments, the conjugate is administered in multiple doses. In certain embodiments, the conjugate is administered sequentially daily for several days. In certain embodiments, the conjugate is administered once per week for 1 month. In certain embodiments, the conjugate is administered once per week for up to 6 months. In certain embodiments, the conjugate is administered for more than a year.
[0245] According to certain embodiments, the conjugate can be administered simultaneously with the one or more anti-cancer agents, or the conjugate and the one or more anti-cancer agentsare administered sequentially, or administration of the one or more anti-cancer agents begins about 1 to about 10 days before administration of the conjugate, or ad ministration of the conjugate thereof begins about 1 to about 10 days before administration of the one or more anti¬ cancer agents, or administration of conjugate and administration of the one or more anti-cancer agents begins on the same day.
[0246] Combination Then
[0247]
[0248] Aspects of present invention provides, in certain embodiments, a method of treating cancer in a patient in need thereof, comprising administering the conjugate described above. In certain embodiments, the cancer is PSMA positive cancer or malignancy. In certain embodiments, the cancer is a solid tumor. Examples of PSMA positive cancers or malignancies can include, but are not limited to, prostate cancer, thyroid cancer, oral cancer, gastric cancer, colorectal cancer, lung cancer, breast cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, bladder cancer, glioblastoma, follicular lymphoma, brain tumors, multiple myeloma, hepatocellular carcinoma, osteosarcoma, hepatocellular cholangiocarcinoma, melanoma, thymoma type b2, GE junction adenocarcinoma, signet-ring cell carcinoma, GI stromal tumor, rectal adenocarcinoma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, and squamous cell carcinoma.
[0249] In certain embodiments, the method further comprises administering an anti-cancer composition. In certain embodiments, the anti-cancer composition comprises, but is not limited to, phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof, chloroquine, hydroxychloroquine (laquenil, Axemal (in India), Dolquine and Quensyl, or a pharmaceutical drug that is an antimalarial or inhibits interactions between lysosomes and autophagasomes that overcome resistance that is linked to autophagy; derivative of triphenylphosphonium (TPP ), PBA, a histone deacetylation inhibitor, a MAPK pathway inhibitor, such as a MEK inhibitor, a RAS inhibitor, and / or RAF inhibitor.
[0250] In certain embodiments, an immunotherapy targeting regulator protein of the immune system is administered with the radiolabeled conjugate. In certain embodiments, the immunotherapy includes anti-CTLA-4 antibodies, anti-PDLl antibodies, anti-PDl antibodies, Toll-like receptor (TLR) agonist, CD40 agonist, and / or anti-ganglioside antibodies. In certain embodiments, the immunotherapy includes CTI. A-4, PDL1 and PD1 inhibitors.In certain embodiments, a radiosensitizing agent is further administered, to enhance the tumor-killing efficacy. In certain embodiments, the radiosensitizing agent includes hyperbaric oxygen, carbogen, nicotinamide, metronidazole, mitomycin-C, tirapazamine, procaine, lidocaine, chlorpromazine, 5-fluorouracil, fluorodeoxyuridine, bromodeoxyuridine, iododeoxyuridine, hydroxyurea, gemcitabine, fludarabine, motexafin, gadolinium, N-ethylmalemide, diamide, diethylmaleate, hyperthermia, paclitaxel, docetaxel, irinotecan)
[0251] In certain embodiments, a DNA damage repair inhibitor is further administered to enhance the tumor-killing efficacy. In some embodiments, the DNA damage repair inhibitor includes PARP inhibitor, ATR inhibitor, CHK inhibitor, WEE1 inhibitor; ATM inhibitor, HDAC inhibitor.
[0252] Preparation of Binding Peptides / Conjugates
[0253] An exemplary embodiment of a binding peptide synthesis and creation of the conjugate is provided herein, for purposes of illustration.
[0254] Materials
[0255] Unsubstituted 2-chlorotritylchloride resin (CTC-resin), [Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), ethyl cyano(hydroxyimino)acetato-O2]tri-l-pyrrolidinylphosphonium hexafluorophosphate (PyOxim), Fmoc-8-aminooctanoic acid (8-AOA), Fmoc-4-aminobutyric acid, (4-ABU), Fmoc-D-Phenylalanine (D-Phe), Fmoc-Lys(Dde)-OH, NH2-Glu(OtBu)-OtBu, and 1 -hydroxybenzotriazole hydrate (HOBt) were obtained either from Aapptec (Louisville, KY) or from Advanced Chemtech (Louisville, KY). Piperidine was obtained from Advanced Chemtech. Polyethylene glycol analogue Fmoc-PEG2-OH was obtained from Broadpharm (San Diego, CA). Diisopropylethylamine (DIPEA), Fmoc-0-Glu(OtBu)-OH, methanol, acetic anhydride, and triisopropylsilane (TIS) were obtained from Sigma Chemical Co. (St. Louis, MO). Acetonitrile (ACN), N, N-Dimethylformamide (DMF), dichloromethane (DCM), Acros brand hydrazine hydrate, diethyl-ether, TCI brand 1,1 ’-carbonyldiimidazole (CDI), and trifluoroacetic acid (TFA) were purchased from Fisher Scientific (Pittsburgh, PA). DO2AtBu monamide-monoacid [Lead specific chelator (PSC)] and p-NCS-benzyl-DO2AtBu-monoamide (bis-tBu-PSC-Bn-NCS) was custom prepared and obtained from CheMatech (Dijon, France). DOTA-di(tBu)ester was obtainedfrom CheMatech as a catalog product. BDH Aristar Ultrapure water was obtained from VWR (Radnor, PA).
[0256] Preparation of tBuO-Glu(OtBu)-uryl-Lys(Dde)-Chlorotrityl Chloride Resin (tBuO-Glu(OtBu)-uryl-Lys(Dde)-CTC-Resin)
[0257] Unsubstituted CTC resin (0.6 mmol / g, 3 g) was reacted with 3 equivalents of Fmoc-Lys(Dde)-OH (1.8 mmol, 0.957 g) in 2.5 mL of DMF was added to the resin suspended in 30 mL of DCM. One equivalent of DIPEA (1.8 mmol, 0.23 g) relative to the amino acid was added to the suspension and allowed to react with while mixing on an orbital shaker. After 15 minutes, an additional 1.5 equivalents of DIPEA were added to the resin slurry and mixed for 1 hour more. After determination of the resin substitution, 2.4 mL of HPLC grade methanol (0.8 mL per gram of resin) was added to cap the resin. The resin was then filtered and washed 3 times with DCM (-50 mL each time. The resin was further washed 2 times with DMF (50 mL each), 2 times with DCM (50 mL each), 3 times with methanol (50 mL each) and allowed to dry under vacuum. After drying, the resin was transferred back to an Erlenmeyer and treated with 50 mL of 25 / 25 / 50 v / v % DCM / DMF / piperidine for 30 minutes and shaken to remove the Emoc protecting group. The resin then was washed with twice with DMF (50 mL each). To test for complete removal of the Fmoc, a small amount of resin was further wash with 2 times with DCM (10 mL each) and 3 times with methanol (10 mL each) and allowed to dry. The test sample of resin was then treated with 0.1 mL of a 12.5:87.5 v / v % solution of acetic acid / DCM for 30 minutes at room temperature, evaporated, and dissolved with 1 mL of a 50 / 50 v / v % solution of H2O / ACN. Absence of Fmoc-Lys(Dde)-OH was confirmed by LC-MS analysis. The main resin batch was then filtered and washed with DMF, DCM, and methanol as described above. Resin substitution was determined to be 0.359 mmol / g.
[0258] To install the uryl group, 0.5 mmol (1.393 g) of resin was added to a manual peptide synthesis flask and swelled with DMF. A 5-fold excess of CDI (2.5 mmols, 0.405 g) was dissolved in DMF and added to the resin slurry followed by addition of 0.5 equivalents (relative to CDI) of DIPEA 1.25 mmol, 0.161 g) and the slurry (-12.5 mL) was agitated with nitrogen. At 4 hours, a small amount of resin was removed and washed with DMF, DCM, and methanol. The resin was analyzed by Kaiser test (Kaiser E, Colescott RL, Bossinger CD, Cook PL Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem.
[0259] 1970;34(2):595-598. doi:10.1016 / 0003-2697(70)90146-6.), which was negative, indicating that the reaction was complete as a negative test suggest that no free amines remain. The resin was then treated immediately by adding 5-equivalents of NH2-Glu(OtBu)-OtBu (2.5 mmols, 0.7395 g) dissolved in DMF followed by addition of DIPEA (1.25 mmols, 0.163 g) and allowed to react for~15 hours with N2 agitation. The resin was then washed with DMF, DCM, and DMF. A small amount of resin was then treated with 0.2 mL of cleavage cocktail of TFA / H2O / TIS (95 / 2.5 / 2.5 %) for two hours, dried by centrifugal evaporation, and reconstituted in 75 / 25 v / v% H2O / ACN and analyzed by LC-MS to confirm the presence of the Glu-uryl-Lys(Dde).
[0260] Automated Synthesis to Add Fmoc-4-Abu-dPhe-dPhe-8-AOA-OH to tBuO-Glu(OtBu)-uryl-Lys(NH2)-CTC Resin
[0261] 340 mg (0.1 mmol) of resin was added to 3 separate wells of the AAPTEC Apex 396 automated multiple peptide synthesizer (Louisville, KY) reaction block. Prior to adding the branch sequence, the Dde was removed from the lysine residue by treating the resin with 5 mL of 2% hydrazine in DMF, mixed for 3 minutes and filtered. This process was repeated 3 more times and washed with DMF and DCM. Complete removal of Dde was confirmed by LC-MS analysis. The branch consisting of Fmoc-4-Abu-D-Phe-D-Phe-8-AOA was synthesized by standard Fmoc procedures employing HATU and 9-hydroxybenzotriazole triple couplings for all amino acids. Capping with acetic anhydride was employed following amino acid coupling. The final Fmoc was removed with a 25 v / v % piperidine / DMF solution to enable further derivatization.
[0262] Synthesis of VMT-PSMA-3B (Formula 7): Formation of the Dimeric Targeting Ligand with Fmoc-β-Glu-OH
[0263] Fmoc-β-Glu-OH (0.06 mmol, 22.2 mg) was dissolved in DMF and added to 0.1 mmol of tBuO-Glu(OtBu)-uryl-Lys(NH2-4-Abu-dPhe-dPhe-8-AOA)-CTC resin to form the dimeric peptide. PyOxim (0.25 mmol, 131.9 mg), HOBt (0.25 mmol, 38.28 mg) and DIPEA (1 mmol, 0.129 g) were added to initiate the coupling reaction which was allowed to proceed for ~14 hours. After confirmation that the reaction was complete by Kaiser test, the Fmoc was removed by treating the resin 3 times with 25 / 75 v / v % piperidine / DMF. The resin was then washed with DMF, DCM, methanol, and dried. Prior to proceeding with the next step in the reaction, a small amount of resin was deprotected and cleaved from the resin with 0.2 mL of a cleavage cocktail consisting of 95:2.5:2.5 v / v / v % TFA: TIS: H2O for 1 hour and dried by centrifugal evaporation. Upon reconstitution, the sample was analyzed by LC-MS and confirmed the desired product was the major peak in the chromatograph.
[0264] Fmoc-PEG2-OH was coupled to the resin with HATU / HOBt / DIPEA with orbital shaking for ~14 hours. Completeness of coupling was determined by Kaiser test and the Fmoc was removed by treating the resin 3 times with 25 / 75 v / v % piperidine / DMF. To complete the analogue, bis-tBu-PSC-Bn-NCS (0.5 mmols, 0.330 g) was dissolved in 3 mL of DMF, added to the pre-swelled resin followed by addition of neat DIPEA (1.43 mmol, 0.185 g) and the reaction was allowed to proceed for 6 hours as the Kaiser test revealed a negative free amine result. The resin was then filtered, washed with DMF, DCM, and methanol. Prior to proceeding with the large scale deprotection and cleavage, a small amount of resin was deprotected and cleaved from the resin with 0.2 mL of a cleavage cocktail consisting of 95:2.5:2.5 v / v / v % TFA: TIS: H2O for 2 hours and dried by centrifugal evaporation. Upon reconstitution, the sample was analyzed by LC-MS and confirmed the desired product was the major peak in the chromatograph
[0265] Peptide Cleavage and Deprotection Conditions
[0266] The peptides were removed from the resin and side chain deprotected using a cleavage cocktail of TFA / H₂O / TIS (95 / 2.5 / 2.5 %) for two hours followed by precipitation in ice cold diethyl-ether for approximately 30 minutes. The precipitate was centrifuged at 4000 rpm for 10 minutes at 4°C and the supernatant decanted. The crude peptides were reconstituted in ultrapure water and placed on dry ice to freeze. Once frozen, the crude peptides were placed on a Labconco Freezone One freeze dryer to lyophilize. The lyophilized peptides were reconstituted in 50 / 50 v / v % ultrapure water / acetonitrile and the crude peptide yield and concentration were determined by UV / Vis spectroscopy.
[0267] The lyophilized peptides were reconstituted in ultrapure water and purified to homogeneity with a Dionex Ultimate 3000 semipreparative RP-HPLC system by injecting the crude material onto a Vydac 218TP 10 μm C18 column (10 x 25 cm) eluted with 0.1 v / v % TFA using a 10-65 v / v % ACN gradient at 5 ml / min over 30 min while monitoring UV absorbance at 280 nm (PSMA-3B). The major peak was collected and pooled from multiple runs, lyophilized, and stored at -20°C. The PSMA-3B purified peptide was reconstituted in PBS and quantified by Abs at 280 nm to determine isolated yield. Purified peptides were characterized by LC-MS on an Agilent 1200 series HPLC interfaced with an Agilent 1956B LC / MSD SL MS by injecting peptide onto an Agilent Zorbax Eclipse XBD-C18 analytical column (4.6 x 150 cm) eluted at 0.7 ml / min with 0.1v / v % TFA and an acetonitrile gradient of 5-80 v / v% over 10 minutes. Mass spectral data was obtained in the positive mode.
[0268] In further embodiments, enumerated as Embodiments 1-51 below, the present disclosure comprises the following.
[0269] Embodiment 1. A conjugate according to Formula 1 below or a pharmaceutically acceptable salt thereof, wherein
[0270] Li, L2 and L3 are independently a linker or a bond;
[0271] Ti and T2 are independently a prostate-specific membrane antigen (PSMA) targeted peptide; and
[0272] Bpis a branching moiety that connects T 1, T2 and chelator A,
[0273]
[0274] Formula 1
[0275] Embodiment 2. The conjugate according to Embodiment 1, wherein the conjugate further comprise a radioisotope.
[0276] Embodiment 3. The conjugate according to Embodiment 2, wherein the radioisotope is divalent.
[0277] Embodiment 4. The conjugate according to Embodiment 2, wherein the conjugate comprises a radioisotope of lead or copper that is coordinated by chelator A.
[0278] Embodiment 5. The conjugate according to Embodiment 4, wherein the lead radioisotope is203Pb or212Pb.
[0279] Embodiment 6. The conjugate according to Embodiment 4, wherein the copper radioisotope is64Cu or67Cu.Embodiment 7. The conjugate according to any preceding Embodiment, wherein the conjugate corresponds to Formula 2 below or a pharmaceutically acceptable salt thereof,
[0280]
[0281] Formula 2
[0282] wherein
[0283] Li, L2 and L3 are independently a linker or a bond; and
[0284] Ti and T2 are independently a prostate-specific membrane antigen (PSMA) targeted peptide.
[0285] Embodiment 8. The conjugate according to any one of Embodiments 1-6, wherein the conjugate corresponds to Formula 3 below, wherein
[0286] Li, L2 and L3 are independently a linker or a bond;
[0287] Embodiment 3. Ti and T2 are independently a prostate-specific membrane antigen (PSMA) targeted peptide; and
[0288] ring D is a cyclic moiety that connects Ti, T2, and chelator A,
[0289]
[0290] Embodiment 9. The conjugate according to any one of Embodiments 1-6, wherein the conjugate corresponds to Formula 4 below or a pharmaceutically acceptable salt thereof
[0291]
[0292] Formula 4
[0293] wherein
[0294] Li, L2 and L3 are independently a linker or a bond; and
[0295] Bpis a branching moiety that connects Li, L2 and L3.Embodiment 10. The conjugate according to Embodiment 9, wherein the conjugate corresponds to Formula 5 below or a pharmaceutically acceptable salt thereof,
[0296]
[0297] wherein Li, L2 and L3 are independently a linker or a bond.
[0298] Embodiment 11. The conjugate according to Embodiment 9, wherein the conjugate corresponds to Formula 6 below or a pharmaceutically acceptable salt thereof,
[0299]
[0300] whereinLi, L2 and L3 are independently a linker or a bond; and
[0301] ring D is a cyclic moiety that connects Ti, T2, and chelator A.
[0302] Embodiment 12. The conjugate according to any one of Embodiments 1-6, 8 and 11, wherein ring D is an optionally substituted 5 to 10-member carbocycle or heterocycle, which may be aromatic or non-aromatic.
[0303] Embodiment 13. The conjugate according to Embodiment 12, wherein ring D is selected from the group consisting of 5-membered carbocyclic and heterocyclic rings, 6 membered carbocyclic and heterocyclic rings, and 9-membered fused heterocycles.
[0304] Embodiment 14. The conjugate according to Embodiment 13, wherein ring D is selected from the group consisting of substituted or unsubstituted pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, furan, thiophene, benzene, pyridine, pyran, pyrimidine, pyridazine, pyrazine, piperazine, thiazine, oxazine, indole, isoindole, quinoline, isoquinoline, purine, naphthalene, purine, and chroman.
[0305] Embodiment 15. The conjugate according to any proceeding Embodiment, wherein Li and L2 independently comprise a chain of 5 to 20 atoms selected from the group consisting of nitrogen, oxygen, sulfur and optionally substituted carbon atoms, wherein the carbon atoms are optionally substituted with oxo (=0), optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted aralkyl, or optionally substituted heteroaralkyl.
[0306] Embodiment 16. The conjugate according to any proceeding Embodiment, wherein Li and L2 independently comprise a moiety corresponding to the following:
[0307]
[0308] wherein each W is independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl.
[0309] Embodiment 17. The conjugate according to any proceeding Embodiment, wherein Li and L2 independently comprise one or more of the following segments
[0310]
[0311] where n is 0 to 5, and each R is independently hydrogen, -OH, halo, alkyl, or -NH2. Embodiment 18. The conjugate according to any proceeding Embodiment, wherein Li and L2 are
[0312]
[0313] wherein Zi and Z2are independently selected from the group consisting of (i) optionally substituted 5-6 membered carbocycle, (ii) optionally substituted 5-6 membered heterocycle, (iii) optionally substituted 9-10 membered carbocycle, (iv) optionally substituted 9-10 membered heterocycle, and (v) optionally substituted anthracene or optionally substituted acridine, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl.
[0314] Embodiment 19. The conjugate according to any proceeding Embodiment, wherein Li and L2 are
[0315]
[0316] wherein Zi and Z2 are independently selected from the group consisting of (i) optionally substituted 5-6 membered carbocycle, (ii) optionally substituted 5-6 membered heterocycle, (iii) optionally substituted 9-10 membered carbocycle, and (iv) optionallysubstituted 9-10 membered heterocycle, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl.
[0317] Embodiment 20. The conjugate according to any proceeding Embodiment, wherein Li and L2 are
[0318]
[0319] wherein Zi and Z2 are independently selected from the group consisting of (i) optionally substituted 5-6 membered carbocycle, and (ii) optionally substituted 5-6 membered heterocycle, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl.
[0320] Embodiment 21. The conjugate according to any preceeding Embodiment, wherein Li and L2 are
[0321]
[0322] wherein Zi and Z2 are independently selected from the group consisting of (i) optionally phenyl, optionally substituted pyridinyl, optionally substituted imidazyol, and optionally substituted naphthyl, wherein the substituents are selected from the group consisting of halo, hydroxy, amino, and alkyl.
[0323] Embodiment 22. The conjugate according to any preceeding Embodiment, wherein Li and L2 are
[0324]
[0325] wherein Zi and Z2 are phenyl or naphthyl.
[0326] Embodiment 23. The conjugate according to any preceeding Embodiment, wherein L3 is a linker comprising one or more of the following segments:
[0327]
[0328] wherein n is 1 to 10.
[0329] Embodiment 24. The conjugate according to any proceeding Embodiment, wherein L3 comprises a polyethylene glycol moiety, -(CH2CH2O)n- wherein n is 1-10.
[0330] Embodiment 25. The conjugate according to Embodiment 24, wherein n is 2 or 4.
[0331] Embodiment 26. The conjugate according to any one of Embodiments 1-7, 9-10, and 15-22, wherein the conjugate corresponds to Formula 7 below or a pharmaceutically acceptable salt thereof,
[0332]
[0333] Formula 7
[0334] wherein the chelator A optionally coordinates a radioisotope of lead or copper.
[0335] Embodiment 27. The conjugate according to any one of Embodiments 1-7, 9-10, and 15- 25, wherein the conjugate corresponds to Formula 8 below or a pharmaceutically acceptable salt thereof,
[0336]
[0337] wherein the chelator A optionally coordinates a radioisotope of lead or copper.
[0338] Embodiment 28. A method of imaging or diagnosing a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising administering the conjugate of any preceding claim, as radiolabeled with a radionuclide, to the subject, and imaging tissue having the radiolabeled conjugate compound bound thereto.
[0339] Embodiment 29. The method according to Embodiment 28, wherein the radionuclide is a lead radioisotope203Pb or a copper isotope64Cu.
[0340] Embodiment 30. A method of treating a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising administering the conjugate of any preceding claim, as radiolabeled with a radionuclide, to the subject, in a dosage sufficient to kill tumor cells.
[0341] Embodiment 31. The method according to Embodiment 30, wherein the radionuclide is a lead radioisotope212Pb or a copper isotope67Cu.
[0342] Embodiment 32. A method of diagnosing and treating a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising:
[0343] diagnosing the subject by administering the conjugate of any preceding claim to the subject, as radiolabeled with a lead radioisotope203Pb or a copper isotope64Cu, and imaging tissue having the radiolabeled conjugate compound bound thereto to diagnose the subject as being afflicted with the cancer, and
[0344] treating the subject diagnosed as being afflicted by the cancer, by administering the conjugate of any preceding claim to the subject, as radiolabeled with a lead radioisotope212Pb or a copper radioisotope67Cu, in a dosage sufficient to kill cancer cells.
[0345] Embodiment 33. The use of the conjugate according to any preceding Embodiment for medical imaging and / or diagnosis of a subject suffering from cancer, as radiolabeled with a radionuclide.
[0346] Embodiment 34. The use according to Embodiment 33, wherein the radionuclide is203Pb or64Cu.Embodiment 35. The use of the conjugate according to any preceding Embodiment for treatment of a subject suffering from cancer, as radiolabeled with a radionuclide.
[0347] Embodiment 36. The use according to Embodiment 35, wherein the radionuclide is212Pb or67Cu.
[0348] Embodiment 37. An aqueous formulation comprising the conjugate of any preceding claim and as radiolabeled with a lead radioisotope, wherein the formulation comprises a buffer and optionally further comprises a stabilizer selected from the group consisting of ascorbic acid, sodium acetate, gentisic acid, and ethanol.
[0349] Embodiment 38. The aqueous formulation according to Embodiment 37, wherein the lead radioisotope is203Pb (Pb-203), and is provided in the formulation in an amount sufficient to provide a dosage of 50-1000 MBq, 100-700 MBq, and / or 150-500 MBq.
[0350] Embodiment 39. The aqueous formulation according to Embodiment 37, wherein the lead radioisotope is212Pb (Pb-212), and is provided in the formulation in an amount sufficient to provide a dosage of 18-3700 MBq, 37-1850 MBq, and / or 50-370 MBq.
[0351] Embodiment 40. The conjugate and / or method according to any one of Embodiments 1-4, 7-25, 28, 30, 33 and 35, wherein the radionuclide is selected from the group consisting of:
[0352]
[0353] Embodiment 41. The conjugate and / or method according to any one of Embodiments 1-4, 7-25, 28, 30, 33 and 35, wherein the radionuclide is a lead isotope selected from the group consisting of Pb-196, Pb-197, Pb-198, Pb-199, Pb-200, Pb-201, Pb-202, Pb-203, Pb-205, Pb-209, Pb-210, Pb- 211, Pb-212, Pb-213, Pb-214, Pb-215, and Pb-216.
[0354] Embodiment 42. The conjugate and / or method according to Embodiment 41, wherein the lead radioisotope is203Pb (Pb-203) or212Pb (Pb-212).
[0355] Embodiment 43. The conjugate and / or method according to any one of Embodiments 1-4, 7-25, 28, 30, 33 and 35, wherein the radionuclide is a copper isotope selected from the group consisting of Cu-55, Cu-56, Cu-57, Cu-58, Cu-59, Cu-60, Cu-61, Cu-62, Cu-63, Cu-64,Cu-65, Cu-66, Cu-67, Cu-68, Cu-69, Cu-70, Cu-71, Cu-72, Cu-73, Cu-74, Cu-75, Cu-76, Cu-77, Cu-78, Cu-79, Cu-80, Cu-81, Cu-82, Cu-83, and Cu-84.
[0356] Embodiment 44. The conjugate and / or method according to Embodiment 43, wherein the copper radioisotope is64Cu (Cu-64) or67Cu (Cu-67).
[0357] Embodiment 45. The method of imaging or diagnosing the cancer according to any one of Embodiments 28-29, wherein the tissue is imaged via single-photon emission computed tomography (SPECT) imaging, optionally in combination with computed tomography (CT) imaging.
[0358] Embodiment 46. The method according to any one of Embodiments 28-32 and 40-45, wherein the cancer that is associated with overexpression of prostate-specific membrane antigen (PSMA) is any of prostate cancer, thyroid cancer, oral cancer, gastric cancer, colorectal cancer, lung cancer, breast cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, bladder cancer, glioblastoma, follicular lymphoma, brain tumors, multiple myeloma, hepatocellular carcinoma, osteosarcoma, hepatocellular cholangiocarcinoma, melanoma, thymoma type b2, ge junction adenocarcinoma, signet-ring cell carcinoma, gi stromal tumor, rectal adenocarcinoma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, and squamous cell carcinoma.
[0359] Embodiment 47. The method according to Embodiment 46, wherein the cancer is any of prostate cancer, breast cancer, renal cell carcinoma, and lung cancer.
[0360] The following examples are intended to further illustrate the invention. They are not intended to limit the invention in any manner.
[0361] EXAMPLE 1
[0362] Radiolabeling PSMA analogues with
[0363]
[0364] PSMA analogue, PSMA-3B (Formula 7) was synthesized in house. Reference compound, PSMA-617 (Formula below), was purchased from TanzhenBio Co. Ltd.
[0365] 203PbCl2was provided by the University of Alberta (Edmonton, Canada) and purified using chromatographic radiometal separation resin, Pb-Resin (size 25-50 pm, Eichrom Technologies, Lisle, IL, USA) preconditioned in 2 mL 2 M HCI. Purified203Pb was collected by eluting the Pb-resin with 1-2 mL of 1 M pH 6 sodium acetate buffer (NaOAC).Approximately 30-37 MBq of203Pb was labeled with 2-3 nmol of PSMA-617 in 0.25-0.5 ml of 1 M pH 4 NaOAC containing 1 mg / mL sodium ascorbate (at final pH 5.3-5.4) at 80°C for 20 min. For PSMA-3B. the reaction was at room temperature for 20 min. Radiochemical yield was determined by applying 0.5-1 µL of reaction mixture onto an iTLC SG strip (Agilent) developed by 0.1 M sodium citrate as a mobile phase. The iTLC strip was cut in half and the top and bottom half were counted by Perkin Elmer 310 Cobra II gamma counter. The radiochemical yield was calculated as the percentage of the counts from the bottom to the total counts and was typically >97%.
[0366] Reference Compound PSMA-617
[0367]
[0368] EXAMPLE 2
[0369] Stability of labeled peptides in saline
[0370]
[0371] After the radiolabeling, an aliquot of reaction mixture was injected into the Dionex Ultimate 3000 HPLC including an in-line radiodetector for radiochemical purity analysis. The mobile phases are H2O / 0.1%TFA (Solvent A) and acetonitrile (Solvent B) at a flow rate of 1 mL / min with the following gradient of Solvent B over time (5%, 0-2 min; 5-70%, 2-12 min; 70%, 12-13 min; 70-5%, 13-17 min). Fifty microliters of the reaction mixture were added to a vial containing 0.5 ml saline and the mixture was incubated at 37°C for up to 24 hours.
[0372] Radiochemical purity was analyzed by radio-HPLC. As shown in Figs. 1A-1D,203Pb-PSMA-3B was highly stable (>90%) in saline for 24 hours.
[0373] EXAMPLE 3In vitro uptake, internalization and efflux of203Pb labeled peptides in LNCaP cells LNCaP cell is PSMA positive and is used for in vitro tests. LNCaP cells were seeded at a density of 2.0 x 106cells in 24-well plates pretreated with poly-D-lysine 2 days before the assay at 85-90% confluence.2O3Pb-labeled PSMA analogues (Molar activity (MA) as 9.25-18.5 MBq / nmol at time of assay) were diluted in binding medium (RPMI 1640 medium / 0.2% BSA / 0.3 mM 1,10-phenanthroline).
[0374] Binding affinity was evaluated by competitive receptor replacement assay. Approximate 100 kCPMs of2O3Pb-labeled PSMA analogue containing different concentration of PSMA analogue was added to each well and incubated at 37°C for 60 min. The wells were washed with 2 x 1 mL of ice-cold binding medium followed by collection of 2 x 0.5 mL of 0.5 N NaOH lysate. The cell lysates were counted using the gamma counter. Duplicates were set for each concentration of the PSMA analogue, and the tests were repeated for 2 or 3 times for average results. IC50 was determined by GraphPad Prism (V9.1.2). For the binding affinity results, the surface plasmon resonance (SPR) assay using the CM5 chip was used, with the ligand Human PSMA / FOLH1 Protein, Fc Tag, and the immobilized level (RU) was 13560.6. Results are shown in Table 1 and FIGS. 2A-2B.
[0375] Table 1
[0376]
[0377] For internalization assay, LNCaP cells in 24-well plate were washed once with binding medium and 0.3 mL of 100 kCPMs203Pb-labeled radiotracer was added to each well. At 5, 15, 30, 60, 90, and 120 minutes post incubation at 37 °C, cells were washed twice with ice-cold binding medium, and the membrane-bound radioactivity was stripped off by collecting 2 x 1 mL of ice-cold stripping buffer (1.2% acetic acid in 0.5 M NaCl, pH ~ 2) after 10 minutesincubation. The cells were then lysed and collected by 2 x 0.5 mL of 0.5 N NaOH. The radioactivity of each portion (membrane-bound and internalized) was counted via a gamma counter. The tests were performed 3-4 times with biological duplicates for each time point. The internalization profile was presented as the percentage of total, membrane-bound and the internalized radioactivity at each time point over the total tracer input. Results are shown in Fig.
[0378] 3A.
[0379] For efflux analysis, the cells were first incubated with 100 kCPMs203Pb-labeled radiotracers at 37 °C for 2 hours as described in the internalization assay and then were washed twice with warm binding medium to remove the radiotracer. Each well of cells was further incubated with the binding medium at 37 °C. At 10, 30, 60, 90, 120, and 180 minutes, cells were washed, and the surface membrane -bound or internalized radioactivity were collected as described above and measured via a gamma counter. The tests were performed 3-4 times with biological duplicates for each time point. Membrane -bound and the internalized radioactivity were presented as the percentage of gamma counts over the total bound activity at the end of 2-hour incubation ± SD. Results were shown in Fig. 3B.
[0380] EXAMPLE 4
[0381] Biodistribution study and gamma-eye imaging study
[0382] Male nude mice (Envigo, 4-6 weeks old) were inoculated with 8-10 x 106of LNCaP cells in 0.1 mL of PBS: Matrigel (1:1) mixture subcutaneously. Eight to twelve weeks postinoculation, when the tumor xenografts reached the size of 6- 10 mm in one dimension, 4 mice were injected via tail vein with approximate 37 kBq of203Pb-PSMA-3B (MA of 18.5 MBq / nmol) for a 2-hour biodistribution study (n=2). Approximate 148 kBq of PSMA-3B and PSMA-617 (MA of 18.5 MBq / nmol) were administered via tail vein to tumor bearing mice for sequential SPECT imaging and ex-vivo biodistribution was conducted after the 20-h imaging. Blood, tumor, main organs and tissues and were collected, weighted and counted by gamma counter and were calculated as percentage of injected dose per gram of tissue (%ID / g) (n=2). Results are shown in Figs. 4 and 5A-5B. The 203Pb-PSMA-3B compound exhibited good tumor uptake at ~ 10%ID / g at 2 h p.i., and very fast kidney clearance (170%ID / g),
[0383] It should be appreciated that minor dosage and formulation modifications of the composition and the ranges expressed herein may be made and still come within the scope and spirit of the present invention.Having described the invention with reference to particular compositions, theories of effectiveness, and the like, it will be apparent to those of skill in the art that it is not intended that the invention be limited by such illustrative embodiments or mechanisms, and that modifications can be made without departing from the scope or spirit of the invention, as defined by the appended claims. It is intended that all such obvious modifications and variations be included within the scope of the present invention as defined in the appended claims. The claims are meant to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates to the contrary.
[0384] The foregoing description has been presented for the purposes of illustration and description. It is not intended to be an exhaustive list or limit the invention to the precise forms disclosed. It is contemplated that other alternative processes and methods obvious to those skilled in the art are considered included in the invention. The description is merely examples of embodiments. It is understood that any other modifications, substitutions, and / or additions may be made, which are within the intended spirit and scope of the disclosure. From the foregoing, it can be seen that the exemplary aspects of the disclosure accomplishes at least all of the intended objectives.
Claims
CLAIMS1. A conjugate according to Formula 5 or Formula 6 below or a pharmaceutically acceptable salt thereof,whereinthe conjugate comprises chelator A;Li, L2 and L3 are independently a linker or a bond; andring D is a cyclic moiety.
2. A conjugate according to Formula 5 below or a pharmaceutically acceptable salt thereof,whereinthe conjugate comprises chelator A; andLi, L2 and L3 are independently a linker or a bond.
3. A conjugate according to Formula 6 below or a pharmaceutically acceptable salt thereof,whereinthe conjugate comprises chelator A;Li, L2 and L3 are independently a linker or a bond; andring D is a cyclic moiety.
4. The conjugate according to claim 1, wherein the conjugate comprises a radioisotope of lead or copper that is coordinated by chelator A.
5. The conjugate according to claim 4, wherein the lead radioisotope is203Pb or212Pb.
6. The conjugate according to claim 4, wherein the copper radioisotope is64Cu or67Cu.
7. The conjugate according to claim 3, wherein ring D is selected from the group consisting of substituted or unsubstituted pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, furan, thiophene, benzene, pyridine, pyran, pyrimidine, pyridazine, pyrazine, piperazine, thiazine, oxazine, indole, isoindole, quinoline, isoquinoline, purine, naphthalene, purine, and chroman.
8. The conjugate according to any one of claims 1-7, wherein Li and L2 independently comprise one or more of the following segmentswhere n is 0 to 5, and each R is independently hydrogen, -OH, halo, alkyl, or -NH2.
9. The conjugate according to any one of claims 1-7, wherein Li and L2 arewherein Zi and Z2 are phenyl or naphthyl.
10. The conjugate according to any one of claims 1-7, wherein La is a linker comprising one or more of the following segments:wherein n is 1 to 10.
11. The conjugate according to claim 1, wherein the conjugate corresponds to Formula 7 below or a pharmaceutically acceptable salt thereof,Formula 7wherein the chelator A optionally coordinates a radioisotope of lead or copper.
12. The conjugate according to claim 1, wherein the conjugate corresponds to Formula 8 below or a pharmaceutically acceptable salt thereof,Formula 8wherein the chelator A optionally coordinates a radioisotope of lead or copper.
13. A method of imaging or diagnosing a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising administering the conjugate of claim 1, as radiolabeled with a radionuclide, to the subject, and imaging tissue having the radiolabeled conjugate compound bound thereto.
14. The method according to claim 13, wherein the radionuclide is a lead radioisotope203Pb or a copper isotope64Cu.
15. A method of treating a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising administering the conjugate of claim 1, as radiolabeled with a radionuclide, to the subject, in a dosage sufficient to kill tumor cells.
16. The method according to claim 15, wherein the radionuclide is a lead radioisotope212Pb or a copper isotope67Cu.
17. A method of diagnosing and treating a subject suffering from a cancer associated with overexpression of prostate-specific membrane antigen (PSMA), the method comprising:diagnosing the subject by administering the conjugate of claim 1 to the subject, as radiolabeled with a lead radioisotope203Pb or a copper isotope64Cu, and imaging tissue having the radiolabeled conjugate compound bound thereto to diagnose the subject as being afflicted with the cancer, andtreating the subject diagnosed as being afflicted by the cancer, by administering the conjugate of claim 1 to the subject, as radiolabeled with a lead radioisotope212Pb or a copper radioisotope67Cu, in a dosage sufficient to kill cancer cells.
18. An aqueous formulation comprising the conjugate of claim 1 and as radiolabeled with a lead radioisotope, wherein the formulation comprises a buffer and optionally further comprises a stabilizer selected from the group consisting of ascorbic acid, sodium acetate, gentisic acid, and ethanol.
19. The aqueous formulation according to claim 18, wherein the lead radioisotope is203Pb (Pb-203), and is provided in the formulation in an amount sufficient to provide a dosage of 50-1000 MBq, 100-700 MBq, and / or 150-500 MBq.
20. The aqueous formulation according to claim 18, wherein the lead radioisotope is212Pb (Pb-212), and is provided in the formulation in an amount sufficient to provide a dosage of 18-3700 MBq, 37-1850 MBq, and / or 50-370 MBq.
21. The conjugate according to claim 1 or the method according to any one of claims 13-17, wherein the radionuclide is selected from the group consisting of:89Zr,90Y,109Pd,111Ag,149Pm,153Sm,166Ho,99mTc,67Ga,68Ga,197Au,198AU,199AU,105Rh,165Ho,149Pm,70As,71As,72As,73As,74As,76As,77As,213Bi,225Ac,117Sn,201Tl,1231,1311,160Gd,148Nd,89Sr,211At,43Sc,44Sc,51Mn,64Cu,86Y,89Zr,99mTc,1SF,76Br,77Br,111In,123I,124I,125I,152Tb,203Pb,47Sc,67Cu,89Sr,90Y,131I,153Sm,149Tb,161Tb,177LU,186Re,188Re,211At,212Pb,212Bi,223Ra,224Ra,225Ac,226Th, and227Th.
22. The conjugate and / or method according to claim 21, wherein the radioisotope is selected from the group consisting of64Cu (Cu-64),67Cu (Cu-67),203Pb (Pb-203), and212Pb (Pb- 212).
23. The method of imaging or diagnosing the cancer according to any one of claims 13-14, wherein the tissue is imaged via single-photon emission computed tomography (SPECT) imaging, optionally in combination with computed tomography (CT) imaging.
24. The method according to any one of claims 13-17, wherein the cancer that is associated with overexpression of prostate-specific membrane antigen (PSMA) is any of prostate cancer, thyroid cancer, oral cancer, gastric cancer, colorectal cancer, lung cancer, breast cancer, endometrial cancer, ovarian cancer, renal cell carcinoma, bladder cancer, glioblastoma, follicular lymphoma, brain tumors, multiple myeloma, hepatocellular carcinoma, osteosarcoma, hepatocellular cholangiocarcinoma, melanoma, thymoma type b2, ge junction adenocarcinoma, signet-ring cell carcinoma, gi stromal tumor, rectal adenocarcinoma, pancreatic neuroendocrine tumor, adrenocortical carcinoma, and squamous cell carcinoma.
25. The method according to claim 24, wherein the cancer is any of prostate cancer, breast cancer, renal cell carcinoma, and lung cancer.5
